<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Mol Psychiatry</journal-id><journal-title-group><journal-title>Molecular Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">1359-4184</issn><issn pub-type="epub">1476-5578</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39633007</article-id><article-id pub-id-type="pmc">PMC12092274</article-id>
<article-id pub-id-type="publisher-id">2865</article-id><article-id pub-id-type="doi">10.1038/s41380-024-02865-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Lithium normalizes ASD-related neuronal, synaptic, and behavioral phenotypes in DYRK1A-knockin mice</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Roh</surname><given-names>Junyeop Daniel</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Bae</surname><given-names>Mihyun</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1275-2819</contrib-id><name><surname>Kim</surname><given-names>Hyosang</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Yeji</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Yeunkeum</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Cho</surname><given-names>Yisul</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Suho</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Yan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Esther</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Jang</surname><given-names>Hyunjee</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Hyeonji</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7210-5798</contrib-id><name><surname>Kim</surname><given-names>Hyun</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Kang</surname><given-names>Hyojin</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1504-3321</contrib-id><name><surname>Ellegood</surname><given-names>Jacob</given-names></name><xref ref-type="aff" rid="Aff9">9</xref><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Lerch</surname><given-names>Jason P.</given-names></name><xref ref-type="aff" rid="Aff9">9</xref><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Bae</surname><given-names>Yong Chul</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0656-1269</contrib-id><name><surname>Kim</surname><given-names>Jin Young</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5518-6584</contrib-id><name><surname>Kim</surname><given-names>Eunjoon</given-names></name><address><email>kime@kaist.ac.kr</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00y0zf565</institution-id><institution-id institution-id-type="GRID">grid.410720.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 1784 4496</institution-id><institution>Center for Synaptic Brain Dysfunctions, </institution><institution>Institute for Basic Science (IBS), </institution></institution-wrap>Daejeon, 34141 Korea </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05apxxy63</institution-id><institution-id institution-id-type="GRID">grid.37172.30</institution-id><institution-id institution-id-type="ISNI">0000 0001 2292 0500</institution-id><institution>Department of Biological Sciences, </institution><institution>Korea Advanced Institute for Science and Technology (KAIST), </institution></institution-wrap>Daejeon, 34141 Korea </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0417sdw47</institution-id><institution-id institution-id-type="GRID">grid.410885.0</institution-id><institution-id institution-id-type="ISNI">0000 0000 9149 5707</institution-id><institution>Digital Omics Research Center, </institution><institution>Korea Basic Science Institute, </institution></institution-wrap>Cheongju, 28119 Korea </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02fsqa093</institution-id><institution-id institution-id-type="GRID">grid.452636.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 0576 3533</institution-id><institution>Korea Institute of Drug Safety &#x00026; Risk Management, </institution></institution-wrap>Anyang, 14051 Korea </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/040c17130</institution-id><institution-id institution-id-type="GRID">grid.258803.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 0661 1556</institution-id><institution>Department of Anatomy and Neurobiology, School of Dentistry, </institution><institution>Kyungpook National University, </institution></institution-wrap>Daegu, 41940 Korea </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/047dqcg40</institution-id><institution-id institution-id-type="GRID">grid.222754.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 0840 2678</institution-id><institution>Department of Anatomy and BK21 Graduate Program, Biomedical Sciences, College of Medicine, </institution><institution>Korea University, </institution></institution-wrap>Seoul, 02841 Korea </aff><aff id="Aff7"><label>7</label>Bertis Inc, Gwacheon, 13840 Korea </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01k4yrm29</institution-id><institution-id institution-id-type="GRID">grid.249964.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 0523 5253</institution-id><institution>Division of National Supercomputing, </institution><institution>KISTI, </institution></institution-wrap>Daejeon, 34141 Korea </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/057q4rt57</institution-id><institution-id institution-id-type="GRID">grid.42327.30</institution-id><institution-id institution-id-type="ISNI">0000 0004 0473 9646</institution-id><institution>Mouse Imaging Centre, Hospital for Sick Children, </institution><institution>Toronto, </institution></institution-wrap>Ontario, M5T 3H7 Canada </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03qea8398</institution-id><institution-id institution-id-type="GRID">grid.414294.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 0572 4702</institution-id><institution>Bloorview Research Institute, Holland Bloorview Kids Rehabilitation Hospital, </institution><institution>Toronto, </institution></institution-wrap>Ontario, M4G 1R8 Canada </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0172mzb45</institution-id><institution-id institution-id-type="GRID">grid.497865.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 0427 1035</institution-id><institution>Wellcome Centre for Integrative Neuroimaging, University of Oxford, </institution><institution>Oxford, </institution></institution-wrap>Oxfordshire, OX39DU UK </aff></contrib-group><pub-date pub-type="epub"><day>5</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>5</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>30</volume><issue>6</issue><fpage>2584</fpage><lpage>2596</lpage><history><date date-type="received"><day>24</day><month>2</month><year>2024</year></date><date date-type="accepted"><day>29</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Dyrk1A deficiency is linked to various neurodevelopmental disorders, including developmental delays, intellectual disability (ID) and autism spectrum disorders (ASD). Haploinsufficiency of <italic>Dyrk1a</italic> in mice reportedly leads to ASD-related phenotypes. However, the key pathological mechanisms remain unclear and human <italic>DYRK1A</italic> mutations remain uncharacterized in mice. Here, we generated and studied <italic>Dyrk1a</italic>-knockin mice carrying a human ASD patient mutation (Ile48LysfsX2; Dyrk1a-I48K mice). These mice display severe microcephaly, social and cognitive deficits, dendritic shrinkage, excitatory synaptic deficits, and altered phospho-proteomic patterns enriched for multiple signaling pathways and synaptic proteins. Early chronic lithium treatment of newborn mutant mice rescues the brain volume, behavior, dendritic, synaptic, and signaling/synapse phospho-proteomic phenotypes at juvenile and adult stages. These results suggest that signaling/synaptic alterations contribute to the phenotypic alterations seen in Dyrk1a-I48K mice, and that early correction of these alterations by lithium treatment has long-lasting effects in preventing juvenile and adult-stage phenotypes.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Neuroscience</kwd><kwd>Drug discovery</kwd></kwd-group><funding-group><award-group><funding-source><institution>Institute for Basic Science IBS, Korea</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100003725</institution-id><institution>National Research Foundation of Korea (NRF)</institution></institution-wrap></funding-source><award-id>RS-2023-00272290</award-id><award-id>2021R1A2C1007061</award-id><award-id>2022M3H9A2096186</award-id><principal-award-recipient><name><surname>Bae</surname><given-names>Mihyun</given-names></name><name><surname>Kim</surname><given-names>Hyosang</given-names></name><name><surname>Kim</surname><given-names>Hyun</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100003716</institution-id><institution>Korea Basic Science Institute (KBSI)</institution></institution-wrap></funding-source><award-id>C470000</award-id><principal-award-recipient><name><surname>Kim</surname><given-names>Hyosang</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">DYRK1A (dual-specificity tyrosine-phosphorylation-regulated kinase 1&#x02009;A) is a serine/threonine kinase that has been implicated in Down syndrome, a human condition caused by trisomy of chromosome 21. Previous studies of DYRK1A using animal models of Down syndrome mainly focused on phenotypes associated with its overexpression, such as developmental delay, learning and memory impairments, and neuronal and synaptic deficits [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. Meanwhile, recent human genetic studies found that reduced (not increased) <italic>DYRK1A</italic> expression is associated with various neurodevelopmental brain dysfunctions, including developmental delay, microcephaly, autism spectrum disorder (ASD), intellectual disability, and seizures [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>]. The clinical importance of <italic>DYRK1A</italic> downregulation is supported by reports indicating that <italic>DYRK1A</italic> mutations are found in 0.1&#x02013;0.5% of individuals with ASD and/or intellectual disability [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>] and ~0.5% of those with developmental disorders [<xref ref-type="bibr" rid="CR13">13</xref>]. As such, studying relevance of Dyrk1a to the pathophysiology of ASD in human-mimicking animal models is called for.</p><p id="Par3">Previous studies on global <italic>Dyrk1a</italic>-haploinsufficient mice reported neurodevelopmental and ASD-related phenotypes, including reduced viability, developmental delay, microcephaly, behavioral deficits, and neuronal and synaptic alterations [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR20">20</xref>]. These results provide strong face validity for <italic>Dyrk1a</italic> haploinsufficiency and suggest potential mechanisms underlying <italic>Dyrk1a</italic>-related mouse phenotypes. However, no published study has completely described their phenotypic rescue, related causal mechanisms, or in-depth characterization of mice carrying a <italic>DYRK1A</italic> mutation identified in humans.</p><p id="Par4">Here we generated and characterized <italic>Dyrk1a</italic>-knockin mice carrying a human <italic>DYRK1A</italic> mutation (Ile48LysfsX2; termed Dyrk1a-I48K mice). These mice display severe microcephaly, dendritic shrinkage, suppressed excitatory synaptic transmission, and social impairments that are associated with phospho-proteomic changes in signaling pathway-related and synaptic proteins. Early chronic treatment of newborn mutant mice with lithium rescues the brain, behavioral, dendritic, synaptic, and phospho-proteomic phenotypes at juvenile and adult stages. Our work highlights that early lithium treatment triggers mechanisms through which multiple signaling and synaptic proteins exert long-lasting rescue effects in this model.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Materials and Methods</title><sec id="Sec3"><title>Animals</title><p id="Par5">To generate Dyrk1A-I48K knock-in (KI) mice, two nucleotides were removed to replace the 48th isoleucine residue of exon 3 with lysine and introduce a frame shift-generated stop codon (I48K fsX2). A neomycin cassette flanked by FRT (flippase recognition target) elements responsive to the flippase enzyme was added to the intron following exon 3. A subsequent crossing with protamine flp mice, which express flippase in the male germ line (Protamine-Flp mice), removed the cassette and left a residual segment that could be detected by polymerase chain reaction (PCR). Animals were fed <italic>ad libitum</italic> and housed under a 12-h light/dark cycle (light phase from 01:00&#x02009;am to 13:00&#x02009;pm). Genotypes of Dyrk1a-KI HT mice were determined by PCR using the following primer pairs: wild-type [WT] allele (413&#x02009;bp): 5&#x02019;-557GAG AAA GAG AGC TGT TTG CCT TCC G-3&#x02019; (forward) and 5&#x02019;-CAA GCA GTT ACA558AGT TCC AGG CTC C-3&#x02019; (reverse); knockout (KO) allele (589&#x02009;bp), 5-GAG AAA559GAG AGC TGT TTG CCT TCC G-3&#x02019; (forward) and 5&#x02019;-ATG CTG AGA AGG CAG560GTA GGT AAG G-3&#x02019; (reverse); floxed allele (323&#x02009;bp), 5&#x02019;-GAG ATG GCG CAA CGC561AAT TAA TG-3&#x02019; (forward) and 5&#x02019;-CAA GCA GTT ACA AGT TCC AGG CTC C-3&#x02019;562(reverse). Mice were weaned at postnatal day 21 (P21), and mixed-genotype littermates of the same gender were housed together until experiments. Only male mice were used for adult behavior tests, whereas both male and female mice were used for pup and juvenile tests, as indicated in the figure legends. For the majority of this study, we employed a heterozygous KI line in the C57BL/6&#x02009;J background (Dyrk1a-I48KfsX2<sup>KI/+</sup> or KI). Homozygous Dyrk1a-KI mice were generated by shifting the genetic background of Dyrk1a-KI mice from pure C57BL/6&#x02009;J to a hybrid 129&#x02009;Sv;C57BL/6&#x02009;J (50:50) genetic background (termed homozygous/HM Dyrk1a-KI mice). The two original mouse lines (C57BL/6&#x02009;J and 129&#x02009;Sv) were maintained independently for at least five generations before being crossed and/or used to produce the mice for experiments.</p></sec><sec id="Sec4"><title>Ethics approval</title><p id="Par6">Mice were bred and maintained at the mouse facility of Korea Advanced Institute of Science and Technology (KAIST) according to the Animal Research Requirements of KAIST. All experimental procedures were conducted in accordance to the guidelines of Animal Research Requirements on the protection of animals used for scientific purposes (Laboratory Animal Act Law 19918, Jan 2, 2024, Korea) and KAIST Animal Welfare Guidelines, and were approved by the Committee of Animal Research and Ethics at KAIST (KA2023-093-v1).</p></sec><sec id="Sec5"><title>MRI measurement of mouse brain</title><p id="Par7">Mice were anesthetized and intracardially perfused with 10&#x02009;ml of 0.1&#x02009;M PBS containing 10&#x02009;U/ml heparin (PPC, cat#C504805) and 2&#x02009;mM ProHance (Gadolinium contrast agent, Bracco Diagnostics, cat#111181) followed by 10&#x02009;ml of 4% paraformaldehyde/PFA (Cedarlane cat#15710) containing 2&#x02009;mM ProHance. After perfusion, mice were decapitated. The brain and remaining skull structures were incubated in 4% PFA&#x02009;&#x02009;+&#x02009;&#x02009;2&#x02009;mM ProHance overnight at 4&#x02009;&#x000b0;C then transferred to 0.1&#x02009;M PBS containing 2&#x02009;mM ProHance and 0.02% sodium azide for at least seven days before MRI scanning. For the anatomical MRI scans a T2 weighted, three-dimensional fast spin-echo sequence was used, with a cylindrical acquisition of k-space, and with a TR of 350&#x02009;ms, and TEs of 12&#x02009;ms per echo for six echoes, field of view of 20&#x02009;&#x000d7;&#x02009;20&#x02009;&#x000d7;&#x02009;25&#x02009;mm<sup>3</sup> and matrix size&#x02009;=&#x02009;504&#x02009;&#x000d7;&#x02009;504&#x02009;&#x000d7;&#x02009;630 giving an image with 0.040&#x02009;mm isotropic voxels. Total imaging time for this sequence was ~14&#x02009;h.</p></sec><sec id="Sec6"><title>Electrophysiology</title><p id="Par8">Ex-vivo electrophysiological experiments were performed to evaluate excitatory/inhibitory synaptic transmission and extracellular field population recordings. More detailed information on electrophysiology methods is available in Supplementary Information.</p></sec><sec id="Sec7"><title>Transcriptomic analysis</title><p id="Par9">RNA-Seq analysis was performed using i) P21 HT/heterozygous-Dyrk1a-KI mice, ii) P60 HT-Dyrk1a-KI mice, and their WT counterparts. Detailed information on RNA sample preparation and DEG analyses GSEA analyses are described in Supplementary Information.</p></sec><sec id="Sec8"><title>Proteomic analysis</title><p id="Par10">Total and PTM proteomic analyses by LC-MS/MS were performed using i) P21 HT-Dyrk1a-KI mice, ii) P60 HT-Dyrk1a-KI mice, and iii) P60-HM/homozygous-Dyrk1a KI mice and their WT counterparts. Detailed information on the sample preparation, LC-MS/MS analysis and proteome identification are available in Supplementary Information.</p></sec><sec id="Sec9"><title>Behavioral tests</title><p id="Par11">All adult behavioral tests were performed with age-matched male WT and Dyrk1a-KI mice (2&#x02013;5 months). Pup and juvenile tests were conducted using both male and female mice as indicated in the figure legends. All behavioral experiments were carried out during light-off periods, except for the home cage nesting behavioral and Laboras tests. Rest periods of at least 1 day were given between tests. Unless otherwise specified, all data were analyzed using EthoVision XT 10 (Noldus). More details on individual behavioral test schemes are listed in the Supplementary Information.</p></sec><sec id="Sec10"><title>Pharmacological rescue</title><p id="Par12">For pharmacological rescues of behaviors, lithium was indirectly delivered to pups through mammary milk by providing dams with lithium carbonate (Merck #255823) at a concentration of 600&#x02009;mg/liter in drinking water. Dams and pups were treated with lithium starting 3 days after birth through mother&#x02019;s milk until they were able to drink the lithium-containing directly up to P21. At P21, mice were weaned and co-housed in cages containing 3&#x02013;6 mice with the same genetic background. After weaning, mice were fed normal drinking water. Drug-administered dams were not returned to mating cages. We did not directly measure the levels of lithium carbonate and its metabolites in the sera of newborn mice, but a previous study employing the same drug treatment strategy has demonstrated that lithium can reach the blood of newborn mice via mother&#x02019;s milk and reported detailed concentrations of serum fluoxetine and its metabolite during and after the treatment [<xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>].</p></sec><sec id="Sec11"><title>Data acquisition and statistical analysis</title><p id="Par13">Behavioral analyses were performed in a double-blind manner. All data are expressed as mean values with standard error of mean (SEM). All statistical analyses were performed using the GraphPad Prism software (version 7.0). The statistical significance of values is indicated in the figure panels as follows: *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, and ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001. Detailed statistical results are presented in Supplementary Table&#x000a0;<xref rid="MOESM2" ref-type="media">1</xref>.</p></sec></sec><sec id="Sec12" sec-type="results"><title>Results</title><sec id="Sec13"><title>Characterization of <italic>Dyrk1a</italic>-I48K-knockin mice</title><p id="Par14">A protein-truncating mutation in the <italic>DYRK1A</italic> gene (Ile48LysfsX2) was reported in a human autistic individual with the following symptoms: 1) microcephaly, 2) intellectual disability, 3) anxiety, 4) ASD-related social deficits, 5) impaired speech, 6) stereotypic behavior, and 7) febrile seizures [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. To determine if this mutation could yield related deficits in mice, we generated <italic>Dyrk1a</italic>-knockin mice carrying the Ile48Lys (or I48K) mutation (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1a</xref>).</p><p id="Par15">This protein-truncating mutation is located near the N-terminus of the protein; its introduction led to the removal of the whole protein with the truncated N-terminal peptide (48 amino acids) being undetectable, as shown by the ~50% decrease seen in the DYRK1A protein levels of heterozygous <italic>Dyrk1a</italic>-knockin mice (termed &#x02018;Dyrk1a-KI mice&#x02019; hereafter) by immunoblot analyses using both N- and C-terminal antibodies (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1b, c</xref>; Supplementary Table&#x000a0;<xref rid="MOESM2" ref-type="media">1</xref>). Consistent with previous results [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>], homozygous Dyrk1a-KI mice were embryonically lethal.</p><p id="Par16">The embryonic lethality of homozygous Dyrk1a-KI mice led us to assess the temporal expression patterns of <italic>Dyrk1a</italic> during embryonic and postnatal stages. In situ hybridization detected <italic>Dyrk1a</italic> mRNAs in various brain regions, including the olfactory bulb, cortex, hippocampus, and cerebellum <bold>(</bold>Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1d</xref>), similar to the previous results [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. DYRK1A protein levels were relatively high during embryonic and early postnatal stages, then decreased to adult levels at ~ postnatal week 4 (or ~ postnatal day/P28) (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1e</xref>). DYRK1A protein levels were comparable in different brain regions at P14 (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1f</xref>).</p><p id="Par17">Dyrk1a-KI mice displayed developmental delay, as evidenced by decreased body weight; this was more obvious in males than females at juvenile and adult stages (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1g, h</xref>). Brain weight and area and brain/body weight ratios were also decreased in male Dyrk1a-KI mice at postnatal weeks 3 and 8, corresponding to juvenile and adult stages, respectively (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1i</xref>). Gross morphology of the Dyrk1a-KI brain was largely normal, as determined by immunostaining for DAPI (cell body marker), NeuN (neurons), S100&#x003b2; (astrocytes), and neurofilament M (axons) (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1j, k</xref>). These results collectively suggest that <italic>Dyrk1a</italic> deletion leads to neurodevelopmental delays that can be detected at juvenile and adult stages.</p></sec><sec id="Sec14"><title>Severe microcephaly in Dyrk1a-KI mice</title><p id="Par18">Given that the autistic individual with the DYRK1A-I48K mutation displayed microcephaly [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR10">10</xref>] and our Dyrk1a-KI mice showed decreases in their brain weights and areas (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1i</xref>), we further analyzed brain volumes using magnetic resonance imaging (MRI). MRI analyses of 8-week-old Dyrk1a-KI mouse brains indicated that there was global microcephaly, with the strongest reductions (5&#x02013;25%) seen in brain regions of the basal ganglia, diencephalon, and midbrain (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><title>Severe microcephaly in Dyrk1a-KI mice.</title><p><bold>a</bold> Heatmaps showing volumetric changes (largely decreases) in various brain regions of Dyrk1a-KI mice (8 weeks, male) compared with WT mice, as assessed using MRI. (<italic>n</italic>&#x02009;=&#x02009;9 mice [WT, KI], Student&#x02019;s <italic>t</italic>-test). <bold>b</bold> Detailed analysis of brain regions exhibiting reduced volumes in Dyrk1a-KI versus WT mice. The widespread volumetric decreases in various brain regions are further highlighted by the observation that only one subregion shows a small volumetric increase (cingulate cortex area 24a&#x02019;; ~3%; indicated by a white box). (<italic>n</italic>&#x02009;=&#x02009;9 mice [WT, KI], Student&#x02019;s t-test).</p></caption><graphic xlink:href="41380_2024_2865_Fig1_HTML" id="d33e669"/></fig></p><p id="Par19">The specific brain sub-regions that exhibited stronger volumetric decreases included the hippocampal dentate gyrus, cingulate cortex, globus pallidus, nucleus accumbens, medial septum, medial amygdala, hypothalamus, and superior colliculus (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref>). These results collectively suggest that the Dyrk1a-I48K mutation in mice leads to severe microcephaly.</p></sec><sec id="Sec15"><title>Behavioral abnormalities in Dyrk1a-KI mice</title><p id="Par20">To test whether the developmental delay and microcephaly observed in Dyrk1a-KI mice are associated with behavioral abnormalities, we subjected the mutant mice to a battery of behavioral tests. We used male mice for these assays because body weights were significantly decreased only in male mice.</p><p id="Par21">Adult-stage Dyrk1a-KI mice (2&#x02013;5 months) displayed largely normal locomotor activity in the open-field and Laboras tests, which measure movements in novel and familiar environments, respectively (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">2a, b</xref>). These mice also showed normal anxiety-like behaviors in the open-field, elevated plus-maze, and light-dark tests, and normal motor coordination in the rotarod test (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">2a, c&#x02013;e</xref>).</p><p id="Par22">In social/repetitive behavioral tests, adult Dyrk1A-KI mice emitted markedly fewer ultrasonic vocalizations (USVs) during courtship behaviors, although their social interactions were normal in the three-chamber test (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a</xref>; Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">2f</xref>), reminiscent of the speech delay and social deficits observed in the human individual who carries the DYRK1A-I48K mutation [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Repetitive behavior was also altered, as shown by decreased climbing, although self-grooming and rearing were normal (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">2g&#x02013;i</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><title>Behavioral deficits, decreased seizure susceptibility, and reduced excitatory synaptic transmission and density in Dyrk1a-KI mice.</title><p><bold>a</bold> Significant suppression of ultrasonic vocalizations (USVs) in Dyrk1A-KI mice (2&#x02013;3 months; male) versus WT mice, as shown by the number and mean duration of each USV and the total duration of all USVs. (<italic>n</italic>&#x02009;=&#x02009;10 mice [WT], 10 [KI], Student&#x02019;s t-test, Mann-Whitney U test). <bold>b</bold> (right) Increased time spent with a reunited mother in juvenile Dyrk1a-KI versus WT mice (P22; male) (<italic>n</italic>&#x02009;=&#x02009;27 [WT], 25 [KI], two-way ANOVA). (left) The mutant mice showed normal levels of olfactory function in the session performed immediately before the mother-reunification session, as shown by their preference for bedding from the previous nest relative to fresh bedding or empty corners. <bold>c</bold> Decreased seizure susceptibility in Dyrk1a-KI mice (2&#x02013;4 months; male) in the pentylenetetrazolium (PTZ)-induced seizure test. (<italic>n</italic>&#x02009;=&#x02009;12 [WT], 8 [KI], Student&#x02019;s <italic>t</italic>-test). <bold>d</bold> Decreased frequency but not amplitude of mEPSCs in CA1 hippocampal pyramidal neurons (P19&#x02013;21; male). (<italic>n</italic>&#x02009;=&#x02009;11 neurons from 3 mice [WT], 16, 3 [KI], Mann-Whitney U-test, Student&#x02019;s <italic>t</italic>-test). <bold>e</bold> Normal levels of mIPSCs in CA1 hippocampal pyramidal neurons (P21&#x02013;22; male). (<italic>n</italic>&#x02009;=&#x02009;33, 6 [WT], 29, 6 [KI], Student&#x02019;s <italic>t</italic>-test). <bold>f</bold> Decreased density of excitatory postsynaptic densities (PSDs) but no change in their length, thickness, or perforation in the hippocampal CA1 region of Dyrk1a-KI mice (P21; male). Arrows indicate putative excitatory synapses with PSDs apposed to presynaptic axon terminals. Scale bar, 500&#x02009;nm. <bold>g</bold> Normal density, length, and thickness of inhibitory PSDs in the hippocampal CA1 region of Dyrk1a-KI mice (P21; male). Arrows indicate putative inhibitory synapses with PSDs that are apposed to GABA-immunopositive axon terminals. Scale bar, 500&#x02009;nm. (<italic>n</italic>&#x02009;=&#x02009;3 mice [WT, KI], Student&#x02019;s t-test). Significance is indicated as * (&#x02009;&#x0003c;&#x02009;0.05), ** (&#x02009;&#x0003c;&#x02009;0.01), *** (&#x02009;&#x0003c;&#x02009;0.001), or ns (not significant).</p></caption><graphic xlink:href="41380_2024_2865_Fig2_HTML" id="d33e762"/></fig></p><p id="Par23">Learning and memory were moderately suppressed in adult Dyrk1A-KI mice, as evidenced by a decrease in spatial fear memory retrieval at 24&#x02009;h but not at 7 days (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">3a, b</xref>). In contrast, cued fear conditioning and spatial learning and memory were normal in the Morris water maze (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">3c, d</xref>). These results are also reminiscent of the intellectual disability observed in the DYRK1A-I48K human individual [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par24">Juvenile Dyrk1a-KI mice spent more time with their reunited mother after a 30&#x02009;min separation (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2b</xref>), suggestive of anxiety-like behavior and similar to the behavior seen in the DYRK1A-I48K human individual. However, these mice showed locomotor activity and social/repetitive behaviors within the normal range (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">3e-g</xref>). Dyrk1a-KI pups emitted normal levels of USVs when separated from their mothers (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">3h</xref>), indicative of normal anxiety-like behavior.</p><p id="Par25">Collectively, these results suggest that Dyrk1a-KI mice display various behavioral abnormalities in social, repetitive, and cognitive behavioral domains at both juvenile and adult stages.</p></sec><sec id="Sec16"><title>Decreased seizure susceptibility and excitatory synaptic density in the Dyrk1a-KI hippocampus</title><p id="Par26">ASD frequently involves an imbalance of excitation/inhibition in brain functions [<xref ref-type="bibr" rid="CR26">26</xref>&#x02013;<xref ref-type="bibr" rid="CR28">28</xref>]. We thus tested for altered excitability of the Dyrk1a-KI brain by subjecting the mutant mice to the pentylenetetrazolium (PTZ)-induced seizure test. Dyrk1a-KI mice showed markedly decreased levels of PTZ-induced brain excitation (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2c</xref>).</p><p id="Par27">To test if this hypo-excitation of the brain involved synaptic alterations, we measured miniature excitatory and inhibitory postsynaptic currents (mEPSCs and mIPSCs, respectively) in CA1 pyramidal neurons of the hippocampus, as this brain region exhibited detectable <italic>Dyrk1a</italic> expression and volumetric decreases in Dyrk1A-KI mice (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1d, f</xref>; Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Our results revealed that Dyrk1a-KI CA1 pyramidal neurons displayed a decrease in the frequency but not amplitude of mEPSCs at ~P21 (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2d</xref>). In contrast, mIPSCs were normal in both frequency and amplitude in mutant neurons (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2e</xref>). These findings indicate that the mutant mice exhibited a decrease in the ratio of excitatory to inhibitory synaptic transmission.</p><p id="Par28">Electron microscopic analyses revealed that the excitatory synapse density was decreased in the mutant CA1 region: There were fewer postsynaptic densities (PSDs) apposed to presynaptic axon terminals, although the PSDs were normal in their length, thickness, and perforation (a measure of maturation) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2f</xref>). In contrast, inhibitory PSDs were not altered in density, length, or thickness (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2g</xref>). These results suggest that excitatory synaptic density is decreased in the mutant hippocampus.</p><p id="Par29">Interestingly, other measures of excitatory synaptic function were largely normal: There was no change in basal AMPA receptor-mediated synaptic transmission (input-output curve) or the ratio of evoked NMDA to AMPA receptor-mediated currents (NMDA/AMPA ratio), with a moderate change in presynaptic release (paired-pulse ratio) (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">4a&#x02013;c</xref>). There was also no change in measures of synaptic plasticity, including high-frequency stimulation long-term potentiation (HFS-LTP), theta-burst stimulation LTP (TBS-LTP), low-frequency stimulation long-term depression (LFS-LTD), and metabotropic glutamate receptor-dependent LTD (mGluR-LTD) (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">4d&#x02013;g</xref>).</p><p id="Par30">These results collectively suggest that the Dyrk1a-KI mutation in mice decreases hippocampal excitatory synaptic density without affecting inhibitory synaptic density or other measures of excitatory synaptic function (basal transmission, NMDA receptor function, and synaptic plasticity), thereby decreasing the ratio of excitatory-to-inhibitory synaptic transmission.</p></sec><sec id="Sec17"><title>Early lithium treatment rescues dendritic arborization, synaptic transmission and density, brain size, and social behavior in Dyrk1a-KI mice</title><p id="Par31">We hypothesized that the suppressed dendritic arborization and decreased excitatory synaptic density in Dyrk1a-KI mice (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>) may represent key mechanisms underlying the phenotypes of Dyrk1a-KI mice. To test this hypothesis, we set out to treat Dyrk1a-KI mice with lithium, bipolar disorder medication known to exert pleiotropic neurodevelopmental, neuroprotective, and neuro-synaptic effects through multiple mechanisms, including GSK3&#x003b2; inhibition [<xref ref-type="bibr" rid="CR29">29</xref>&#x02013;<xref ref-type="bibr" rid="CR36">36</xref>]. We utilized a chronic treatment during the first 3&#x02013;4 postnatal weeks because: 1) Dyrk1a protein levels remain high until ~P21 (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1d</xref>), 2) behavioral phenotypes were detectable at juvenile stages (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2b</xref>; Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">2</xref> and <xref rid="MOESM1" ref-type="media">3</xref>), 3) excitatory synaptic deficits were observed at juvenile stages (Figs.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>d&#x02013;g and <xref rid="Fig4" ref-type="fig">4</xref>) early corrections of pathological mechanisms can elicit long-lasting effects [<xref ref-type="bibr" rid="CR37">37</xref>]. Specifically, newborn heterozygous Dyrk1a-KI pups (~&#x02009;P0) were treated with lithium through the mother&#x02019;s milk until weaning (~&#x02009;P21) [<xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>], and dendritic arborization, synaptic transmission and density, brain size, proteomic profiles, and mother-seeking behavior were assessed at ~P21 (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref>). After being weaned at ~P21, another set of Dyrk1a-KI pups continued to receive lithium treatment through their drinking water until ~P28. At ~2&#x02013;3 months of age, social communication (adult USVs) and seizure susceptibility were measured, and proteomic profiles were obtained.<fig id="Fig3"><label>Fig. 3</label><caption><title>Early lithium treatment rescues dendritic branching and synaptic transmission and density in Dyrk1a-KI mice.</title><p><bold>a</bold> Schematic depiction of early postnatal chronic lithium treatment and subsequent measurements of dendritic arborization (Sholl analysis), excitatory synaptic transmission (mEPSCs), excitatory synaptic density, brain size, proteomic profiles, and mother-seeking behavior in the maternal homing test at ~P21, and social communication (adult USVs), seizure susceptibility, and proteomic profiles at 2&#x02013;3 months. Lithium carbonate (600&#x02009;mg/L H<sub>2</sub>O) was given to pups via the mother&#x02019;s milk up until weaning at ~P21. At ~P21, lithium-treated mice were randomly selected for Sholl analysis (hippocampus and mPFC), mEPSC recording, EM analysis of excitatory synaptic density (PSD density and shape), brain area measurement, and proteomic analyses. The remaining mice continued to receive lithium treatment via their drinking water until ~P28; they were thereafter given normal drinking water, and behaviors (USV social communication and proteomic profiles were assessed at ~2&#x02013;3 months. <bold>b</bold> Normalized dendric arborization in hippocampal (HP) CA1 pyramidal neurons in lithium-treated Dyrk1a-KI mice (&#x02009;~&#x02009;P21; male), as determined by Sholl analysis. Scale bar, 100&#x02009;&#x003bc;m. (<italic>n</italic>&#x02009;=&#x02009;5 neurons from 3 mice [HP-WT], 7, 3 [HP-KI; Li-untreated], and 7, 3 [HP-KI-Li], one-way ANOVA). <bold>c</bold> Normalized dendric arborization in mPFC (medial prefrontal cortex) prelimbic layer 2 pyramidal neurons (<bold>c</bold>) in lithium-treated Dyrk1a-KI mice (&#x02009;~&#x02009;P21; male), as determined by Sholl analysis. Scale bar, 100&#x02009;&#x003bc;m. (<italic>n</italic>&#x02009;=&#x02009;25, 3 [mPFC-WT], 21, 3 [mPFC-KI; Li-untreated], and 22, 3 [mPFC-KI-Li], one-way ANOVA). <bold>d</bold>, <bold>e</bold> Normalized frequency of mEPSCs in hippocampal CA1 pyramidal neurons in lithium-treated Dyrk1a-KI mice (&#x02009;~&#x02009;P21) with no effects on mIPSCs. (<italic>n</italic>&#x02009;=&#x02009;12 neurons from 3 mice [mEPSC-WT], 13, 3 [mEPSC-KI], 14, 3 [mEPSC-KI-Li], 15, 3 [mIPSC-WT], 16, 3 [mIPSC-KI], 17, 3 [IEPSC-KI-Li], one-way ANOVA). <bold>f</bold>, <bold>g</bold> Normalized density of excitatory synapses (PSDs apposed to axon terminals) without effects on PSD length, thickness, or perforation in the hippocampal CA1 area of lithium-treated Dyrk1a-KI mice (&#x02009;~&#x02009;P21). (<italic>n</italic>&#x02009;=&#x02009;3 mice [WT], 3 [KI], 3 [KI-Li], one-way ANOVA).</p></caption><graphic xlink:href="41380_2024_2865_Fig3_HTML" id="d33e930"/></fig></p><p id="Par32">The early lithium-treated Dyrk1a-KI mice showed normalized dendritic arborization in hippocampal CA1 pyramidal neurons and prefrontal prelimbic pyramidal neurons at ~P21, compared with those of untreated Dyrk1a-KI mice, as determined by Sholl analysis (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3b, c</xref>). In addition, hippocampal neurons of lithium-treated Dyrk1a-KI mice showed a normalized frequency of mEPSCs at ~P21 without effects on mIPSCs (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3d, e</xref>). Consistently, the lithium treatment normalized excitatory synaptic density, as determined by the EM analysis of PSD, without affecting PSD morphology (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3f</xref>).</p><p id="Par33">Remarkably, early lithium-treated Dyrk1a-KI mice showed a normal brain size at ~P21, lacking the microcephaly seen in their untreated counterparts (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4a</xref>). Lithium also restored mother-seeking behavior at ~P21 (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4b</xref>) and courtship USVs (partial) and seizure susceptibility at 2&#x02013;3 months (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4c, d</xref>).<fig id="Fig4"><label>Fig. 4</label><caption><title>Early lithium treatment rescues brain size and behaviors in juvenile and adult Dyrk1a-KI mice.</title><p><bold>a</bold> Normalized brain size in lithium-treated Dyrk1a-KI mice (&#x02009;~&#x02009;P21). Whole-brain areas were measured using top-down brain images. (<italic>n</italic>&#x02009;=&#x02009;3 mice [WT, KI, and KI-Li], one-way ANOVA). <bold>b</bold> Normalized mother-seeking behavior in lithium-treated Dyrk1a-KI mice (P21), as shown by time spent with reunited mother in the maternal homing test. (<italic>n</italic>&#x02009;=&#x02009;12 [WT], 13 [KI], and 13 [KI-Li], one-way ANOVA). <bold>c</bold> Partially normalized courtship USVs in lithium-treated Dyrk1a-KI mice (2&#x02013;3 months), as shown by full normalization of USV call number and partial normalization of total USV duration. (<italic>n</italic>&#x02009;=&#x02009;11 [WT], 13 [WT-Li], 10 [KI], and 11 [KI-Li], two-way ANOVA). <bold>d</bold> Normalized seizure susceptibility in lithium-treated Dyrk1a-KI mice (2&#x02013;3 months), as shown by time spent with reunited mother in the maternal homing test. (<italic>n</italic>&#x02009;=&#x02009;13 [WT], 10 [KI], and 9 [KI-Li], one-way ANOVA). Significance is indicated as * (&#x02009;&#x0003c;&#x02009;0.05), ** (&#x02009;&#x0003c;&#x02009;0.01), *** (&#x02009;&#x0003c;&#x02009;0.001), or ns (not significant).</p></caption><graphic xlink:href="41380_2024_2865_Fig4_HTML" id="d33e985"/></fig></p><p id="Par34">These results collectively suggest that early postnatal and chronic lithium treatment of Dyrk1a-KI mice rescues multiple Dyrk1a-KI phenotypes (dendritic arborization, synaptic transmission and density, brain size, and behavior) both immediately and long after the treatment, and has long-lasting effects in preventing behavioral phenotypes from appearing at adult stages.</p></sec><sec id="Sec18"><title>Posttranslational modifications in early lithium-treated Dyrk1a-KI mice at&#x02009;~&#x02009;P21</title><p id="Par35">To better understand the mechanisms underlying the early lithium-dependent rescue of Dyrk1a-KI phenotypes, we sought to analyze Dyrk1a-KI transcriptomes and proteomes. We used whole-brain samples because Dyrk1a is widely expressed in the brain, and brain volumetric and neuromorphological changes were observed in various brain regions.</p><p id="Par36">The RNA-Seq results from Dyrk1a-KI whole brains at P21 indicated small numbers of differentially expressed genes (DEGs) but, in gene set enrichment analysis (GSEAs) [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>], strong increases in synapse-related gene expressions and &#x0201c;reverse-ASD&#x0201d; transcriptomic patterns (changes opposite to those occurring in ASD) (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">5a&#x02013;d</xref>; Supplementary Table&#x000a0;<xref rid="MOESM3" ref-type="media">2</xref>). These results suggest compensatory transcriptomic changes to normalize excitatory synaptic function at P21. The P60 transcriptome showed reverse-ASD patterns associated with upregulated splicing-related genes and downregulated oligodendrocyte-related genes (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">5e&#x02013;h</xref>; Supplementary Table&#x000a0;<xref rid="MOESM4" ref-type="media">3</xref>), suggestive of compensatory changes that occur through other (or not-synaptic) mechanisms.</p><p id="Par37">We next analyzed total proteomes using WT and Dyrk1a-KI mice at ~P21 and ~P60 and found small numbers of differentially expressed proteins (total-DEPs; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05&#x02009;+&#x02009;FC&#x02009;&#x0003e;&#x02009;1.2; total 13 for P21 [up 8 and down 5]; total 13 for P60 [up 5 and down 8]) (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">6a&#x02013;d</xref>; Supplementary Table&#x000a0;<xref rid="MOESM5" ref-type="media">4</xref>). There were no overlapping DEPs at P21 and P60. This suggests that the Dyrk1a-KI mutation induces small changes in total protein levels at ~P21 and ~P60.</p><p id="Par38">We next attempted to analyze Dyrk1a-KI proteomes with a focus on posttranslational modifications (PTMs), which are known to modulate aspects of protein stability, function, localization, interaction, and stability [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. To this end, we treated WT and Dyrk1a-KI mice with vehicle/lithium during the first three postnatal weeks, analyzed PTM-differentially expressed phosphopeptides (DEPPs), determined baseline differences between vehicle-treated WT mice and vehicle-treated Dyrk1a-KI mice, and identified a subset of baseline differences (vehicle-treated WT/Dyrk1a-KI) that were no longer significantly different between lithium-treated Dyrk1a-KI and vehicle-treated WT mice (termed as &#x02018;lithium-rescued PTM-DEPPs&#x02019;). We further compared PTM-DEPPs obtained at ~P21 versus ~P60 to examine the immediate and long-term effects of early lithium treatment.</p><p id="Par39">The baseline comparison of vehicle-treated WT and vehicle-treated Dyrk1a-KI mice identified a large number of P21 PTM-DEPPs (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05&#x02009;+&#x02009;FC&#x02009;&#x0003e;&#x02009;1.2; 766 total, 336 upregulated (&#x02018;up&#x02019;) and 430 downregulated (&#x02018;down&#x02019;)) (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">7a</xref>; Supplementary Table&#x000a0;<xref rid="MOESM6" ref-type="media">5</xref>). Given the small numbers of total DEPs mentioned above (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">6a</xref>, b), these PTM changes seem to mainly reflect changes in protein phosphorylation levels rather than total protein levels. Many of the PTM-DEPPs with stronger changes (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05&#x02009;+&#x02009;FC&#x02009;&#x0003e;&#x02009;2.0) were among the synaptic proteins listed in the SynGO database [<xref ref-type="bibr" rid="CR42">42</xref>]; these included Dock4 (dedicator of cytokinesis 4]), Elavl2 (ELAV-like RNA-binding protein 2), Dagla (diacylglycerol lipase alpha), Prkcd (protein kinase C delta), Prr7 (proline-rich 7), and Map2 (microtubule-associated protein 2) (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">7b</xref>).</p><p id="Par40">DAVID analyses using the KEGG database [<xref ref-type="bibr" rid="CR43">43</xref>] indicated that the PTM-DEPPs (766 peptides) were enriched for various signaling pathways, including the insulin, cAMP, oxytocin, AMPK, ErbB, thyroid hormone, gap junction, and autophagy pathways (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">7c</xref>). DAVID analyses using the gene ontology (GO) database [<xref ref-type="bibr" rid="CR44">44</xref>] indicated that the PTM-DEPPs were enriched for &#x02018;postsynaptic density&#x02019; and &#x02018;protein binding&#x02019; (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">7c</xref>). Consistently, the PTM-DEPPs were found to be enriched for SynGO proteins/functions (21&#x02013;27%) (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">7d</xref>). These results suggest that the P21 PTM-DEPPs may affect various signaling pathways and synaptic proteins to induce the dendritic/synaptic deficits observed in juvenile Dyrk1a-KI mice.</p><p id="Par41">We next compared PTM-DEPPs from P21 vehicle-treated WT mice and lithium-treated Dyrk1a-KI mice, highlighting the lithium-rescued PTM-DEPPs in volcano plots of the baseline difference between vehicle-treated WT mice and vehicle-treated Dryk1a-KI mice (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5a</xref><bold>;</bold> Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">8a</xref>; Supplementary Table&#x000a0;<xref rid="MOESM6" ref-type="media">5</xref>). DAVID-KEGG analyses indicated the lithium-rescued PTM-DEPPs (561 total; 228 up and 333 down) are enriched for ~80% of the signaling pathways that were identified from the baseline difference analysis (8 out 10 pathways, namely the insulin, cAMP, oxytocin, AMPK, gap junction, longevity, ErbB, and autophagy pathways) (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5b</xref>). DAVID-GO analyses indicated that the lithium-rescued PTM-DEPPs were enriched for &#x02018;postsynaptic density&#x02019; and &#x02018;protein binding&#x02019; (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5b</xref>), and therefore resembled the DAVID-GO enrichment pattern at baseline (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">7c</xref>). The lithium-rescued PTM-DEPPs were enriched for SynGO proteins/functions (24&#x02013;31%) (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">8b</xref>), further resembling the pattern seen at baseline (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">7d</xref>). Notably, the lithium-rescued SynGO PTM-DEPPs included Elavl2 (S221) and Kalrn (S488), whose decreased phosphorylations were restored to WT levels after lithium treatment (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5b</xref>). The functions of these phosphorylations remain unclear, but Elavl2 is detected at synapses and regulates synapse assembly [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>] and dendritic arborization [<xref ref-type="bibr" rid="CR47">47</xref>]. In addition, Kalrn (Kalirin), a Rho guanine nucleotide exchange factor (Rho-GEF) implicated in neurodevelopmental disorders, including schizophrenia [<xref ref-type="bibr" rid="CR48">48</xref>], regulates synaptic functions and dendritic arborization [<xref ref-type="bibr" rid="CR49">49</xref>].<fig id="Fig5"><label>Fig. 5</label><caption><title>Rescue of P21 and P60 PTM-DEPPs by early lithium treatment of Dyrk1a-KI mice.</title><p><bold>a</bold> Volcano plot presentation of PTM-DEPPs at ~P21 that are significantly altered in the baseline condition (vehicle-treated WT and vehicle-treated heterozygous Dyrk1a-KI) but are rescued by early chronic lithium treatment (P0&#x02013;21) and thus are no longer significantly different (<italic>p</italic>&#x02009;&#x0003e;&#x02009;0.05) between lithium-treated Dyrk1a-KI mice and vehicle-treated WT mice (termed as &#x02018;lithium-rescued PTM-DEPPs&#x02019;). The rescued PTM-DEPPs are highlighted as green dots (vehicle-treated WT vs. lithium-treated Dyrk1a-KI mice) among those showing the baseline difference (gray dots; vehicle-treated WT vs. vehicle-treated Dyrk1a-KI mice). (<italic>n</italic>&#x02009;=&#x02009;3 mice [WT-Veh, KI-Veh, and KI-Li]). <bold>b</bold> DAVID-KEGG/gene ontology (GO) analyses of the lithium-rescued P21 and P60 PTM-DEPPs (up and down pooled). <bold>c</bold> A volcano plot showing early (P0&#x02013;28) lithium-rescued ~P60 PTM-DEPPs (green dots; no longer significantly different between lithium-treated Dyrk1a-KI mice and vehicle-treated WT mice) overlaid onto the baseline ~P60 PTM-DEPPs (gray dots; vehicle-treated WT vs. vehicle-treated Dyrk1a-KI mice). (<italic>n</italic>&#x02009;=&#x02009;3 mice [WT-Veh, KI-Veh, and KI-Li]). <bold>d</bold> DAVID-KEGG/gene ontology (GO) analyses of the lithium-rescued P60 PTM-DEPPs (up and down pooled).</p></caption><graphic xlink:href="41380_2024_2865_Fig5_HTML" id="d33e1150"/></fig></p><p id="Par42">These results collectively suggest that early chronic lithium treatment of Dyrk1a-KI mice rescues the PTM patterns of various signaling and synaptic proteins seen immediately after weaning (~&#x02009;P21).</p></sec><sec id="Sec19"><title>Posttranslational modifications in early lithium-treated Dyrk1a-KI mice at&#x02009;~&#x02009;P60</title><p id="Par43">When PTM-DEPPs were analyzed at ~P60 to assess the long-term effects of early lithium treatment (P0&#x02013;P28), the baseline comparison of vehicle-treated WT and vehicle-treated Dyrk1a mice revealed many P60 PTM-DEPPs (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05&#x02009;+&#x02009;FC&#x02009;&#x0003e;&#x02009;1.2; 306 total, 220 up and 86 down) (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">9a</xref>; Supplementary Table&#x000a0;<xref rid="MOESM7" ref-type="media">6</xref>). Some synaptic proteins exhibited strongly upregulation of their P60 PTM-DEPPs (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05&#x02009;+&#x02009;FC&#x02009;&#x0003e;&#x02009;2.0), including SynGO proteins (e.g., Shank3 and Shank2), Psd3 (pleckstrin and sec3 domain-containing 3), Kif1a (kinesin family member 1&#x02009;A), Crk (CRK proto-oncogene, adaptor protein), Pura (purine-rich element binding protein A), Kcnma1 (potassium calcium-activated channel subfamily M alpha 1), Kif21a (kinesin family member 21&#x02009;A), and Aak1 (AP2-associated kinase 1) (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">9b</xref>). In DAVID-KEGG analyses, P60 PTM-DEPPs were enriched for certain synapse-related pathways, including the &#x02018;glutamatergic synapse&#x02019;, &#x02018;GABAergic synapse&#x02019;, and &#x02018;synaptic vesicle cycle&#x02019; pathways (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">9c</xref>). This result differed from those observed at P21, when various signaling pathways were more strongly enriched (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">7c</xref>). DAVID-GO analyses showed that P60 PTM-DEPPs were enriched for &#x02018;postsynaptic density&#x02019;, &#x02018;postsynaptic density&#x02019;, and &#x02018;protein binding&#x02019; (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">9c</xref>), which was similar to the results obtained from P21 PTM-DEPPs (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">5c</xref>). Surprisingly, SynGO analyses revealed that P60 PTM-DEPPs showed a notable synaptic enrichment for SynGO proteins/functions (&#x02009;~&#x02009;46%/38%) (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">9d</xref>) that was ~2-fold greater than that seen for P21 PTM-DEPPs (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">7d</xref>). These results suggest that P60 PTM-DEPPs differ from P21 PTM-DEPPs: The former are less enriched for signaling pathways but more strongly enriched for synaptic proteins.</p><p id="Par44">We next identified P60 PTM-DEPPs in vehicle-treated WT mice versus lithium-treated Dyrk1a-KI mice and compared them to the baseline PTM-DEPPs to identify lithium-rescued PTM-DEPPs (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5c</xref>; Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">8c</xref>; Supplementary Table&#x000a0;<xref rid="MOESM7" ref-type="media">6</xref>). The P60 lithium-rescued PTM-DEPPs (78 total, 41 up and 37 down) included various synaptic proteins, including Bsn (bassoon presynaptic cytomatrix protein), Ap1s1 (adaptor-related protein complex 1 subunit sigma 1), Dock10 (dedicator of cytokinesis 10), Sv2b (synaptic vesicle glycoprotein 2B), Marcks (myristoylated alanine rich protein kinase C substrate), Cap2 (cyclase-associated actin cytoskeleton regulatory protein 2), Kcnc1 (potassium voltage-gated channel subfamily C member 1), Ctnnd2 (catenin delta 2), Pak3 (p21 (RAC1)-activated kinase 3), and Tsc1 (TSC complex subunit 1) (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">8c</xref>). DAVID-KEGG/GO analyses revealed that the lithium-rescued PTM-DEPPs were strongly enriched for synapse-related functions (i.e., &#x02018;postsynaptic density&#x02019;) (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5d</xref>). The lithium-rescued PTM-DEPPs were strongly enriched for SynGO proteins/functions (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">8d</xref>). There was no overlap between P21 and P60 lithium-rescued PTM-DEPPs.</p><p id="Par45">Lastly, homozygous (rather than heterozygous) Dyrk1a-KI mice at ~P60 were analyzed for PTM-DEPPs. Homozygous Dyrk1a-KI mice could be born in a hybrid background (C57/BL6J x 129&#x02009;Sv), but at a very low Mendelian ratio (1:1:0.015 for WT/heterozygous/homozygous rather than 1:2:1). Thus, they could not be used to examine other phenotypes. This analysis identified numerous PTM-DEPPs (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05&#x02009;+&#x02009;FC&#x02009;&#x0003e;&#x02009;1.2; 223 total, 152 up and 71 down) (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">10a</xref>; Supplementary Table&#x000a0;<xref rid="MOESM8" ref-type="media">7</xref>). The PTM-DEPPs identified as having stronger changes (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05&#x02009;+&#x02009;FC&#x02009;&#x0003e;&#x02009;1.2) included not only synaptic proteins but also mTOR and other signaling proteins (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">10b</xref>). DAVID and SynGO analyses supported these results (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">10c, d</xref>). The findings differed from those obtained in heterozygous Dyrk1a-KI mice, where the main changes were observed in synaptic but not signaling proteins. This indicates that there may be distinct gene-dosage effects.</p><p id="Par46">Together, our results suggest that: 1) P60 PTM-DEPPs are enriched more for synaptic proteins than signaling proteins, and thus show a pattern that differs from that of P21 PTM-DEPPs; 2) early lithium treatment of Dyrk1a-KI mice preferentially rescues synaptic protein PTMs relative to signaling protein PTMs in the baseline difference long after the treatment (i.e., at ~P60); and 3) early lithium treatment may rescue signaling protein PTMs at ~P21 to rescue synaptic protein PTMs at ~P60.</p></sec><sec id="Sec20"><title>Functional characterization of lithium-rescued PTM-DEPPs in Dyrk1a-KI mice</title><p id="Par47">We next attempted to further understand the mechanisms underlying the lithium-rescued PTM-DEPPs. We tested if the activity of GSK3&#x003b2;, known to be inhibited by lithium and regulate synaptic and neuronal functions [<xref ref-type="bibr" rid="CR29">29</xref>&#x02013;<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR50">50</xref>], was affected by examining the proteomic results for changes in GSK3&#x003b2;-Ser9 phosphorylation and by immunoblot analysis using P21 and P60 Dyrk1a-HT brain lysates. This was also combined with the analysis of potential GSK3&#x003b2;-upstream kinases using the method previously reported [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>].</p><p id="Par48">Phosphorylation of GSK3&#x003b2; at Ser9 showed no significant changes, as indicated by the total and PTM proteomic analyses in P21 and P60 Dyrk1a-HT mice (Supplementary Figs.&#x000a0;<xref rid="MOESM1" ref-type="media">6</xref>, <xref rid="MOESM1" ref-type="media">7</xref>, <xref rid="MOESM1" ref-type="media">9</xref>). Immunoblot analyses also indicated total and GSK3&#x003b2;-Ser9 phosphorylation levels were comparable between P21 WT and Dyrk1a-KI mice (Supplementary Figs.&#x000a0;<xref rid="MOESM1" ref-type="media">11</xref>a and <xref rid="MOESM1" ref-type="media">12</xref>). Accordingly, potential GSK3&#x003b2;-upstream kinases, including calcium/calmodulin-dependent kinase (CaMK) group/family kinases (i.e., CAMK1&#x02013;4 and CAMKK), determined as previously reported [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>], did not show altered phosphorylations in the PTM-DEPPs from P21 and P60 Dyrk1a-HT mice (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">11b</xref>). These results suggest that GSK3&#x003b2; is less likely to be important for Dyrk1-HT phenotypes.</p><p id="Par49">Using the same method [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>], we sought to identify potential upstream kinases responsible for the downregulated and lithium-responsive PTM-DEPPs in P21 wild-type and Dyrk1a-KI mice. Downregulated PTM-DEPPs were primarily analyzed as they are more likely to represent direct potential substrates of the upstream kinases. Among the candidate upstream kinases for the top 31 downregulated P21 PTM-DEPPs, 24% belonged to the CMGC (<underline>C</underline>DKs, <underline>M</underline>APKs, <underline>G</underline>SKs, <underline>C</underline>LKs) group kinases, where DYRK1A belongs to CLKs, and 13% to the STE group (STE20/11/7) (Supplementary Fig&#x000a0;<xref rid="MOESM1" ref-type="media">11c</xref>). For the top 22 downregulated P60 PTM-DEPPs, 14% of upstream kinases belonged to the CMGC group, 12% to the CAMK group, and 9% to the STE group (Supplementary Fig&#x000a0;<xref rid="MOESM1" ref-type="media">11d</xref>). These results suggest that some of the top downregulated P21/P60 PTM-DEPPs likely represent direct substrates of DYRK1A.</p><p id="Par50">We then investigated the functions of several PTM-DEPPs, as their roles remain uncharacterized. Specifically, we focused on Kalirin and Elavl2, which are known to regulate synaptic function and dendritic arborization [<xref ref-type="bibr" rid="CR45">45</xref>&#x02013;<xref ref-type="bibr" rid="CR49">49</xref>], although Elavl2 showed relatively lower scores for Dyrk1a/GSK3&#x003b2;-dependent phosphorylation compared to Kalirin. Given that the phosphorylation sites of these proteins, Kalirin-S488 and Elavl2-S221, are not well characterized, we generated phospho-mimic (Kalirin-7-S488D and Elavl2-S221D) and non-phosphorylatable mutants (Kalirin-7-S488A and Elavl2-S221A). These mutants were then tested for their functions in cultured wild-type (WT) and Dyrk1a-HT knock-in (KI) hippocampal neurons. Kalirin-7-S488D (phospho-mimic) overexpressed in cultured neurons enhanced the dendritic arborization of both WT and Dyrk1a-HT neurons, as measured by Sholl analysis and compared to its non-phosphorylatable form (Kalirin-7 S488A) (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">11e, f</xref>). Likewise, Elavl2-S221D increased dendritic arbors of WT and Dyrk1a-HT neurons, as compared to Elavl2-S221A (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">11e, f</xref>). These results suggest that Kalirin-S448 and Elavl2-S221 phosphorylations may regulate dendritic arborizations in hippocampal neurons and are consistent with the suppressed dendritic arborization in Dyrk1a-HT mice (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3b</xref>).</p></sec></sec><sec id="Sec21" sec-type="discussion"><title>Discussion</title><p id="Par51">Here, we generated Dryk1a-KI mice carrying a patient-derived Dyrk1a-KI mutation (I48&#x02009;K), characterized their phenotypes at proteomic, synaptic, neuronal, brain, and behavioral levels, and demonstrated that early postnatal chronic lithium treatment can prevent these phenotypes from appearing at juvenile and adult stages.</p><p id="Par52">A key phenotype of our Dyrk1a-KI mice is severe microcephaly accompanied by brain volume decreases of 5&#x02013;25% across different regions (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). These region-specific decreases may reflect varying levels of Dyrk1a expression or interactions with other mechanisms. While further investigation is needed, the significant and widespread brain volume reductions are consistent with the microcephaly observed in the human individual carrying the I48K mutation [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. One possible mechanism underlying this phenotype could be the signaling pathway alterations reflected in the P21 PTM-DEPPs, which suggested changes in insulin, cAMP, oxytocin, AMPK, gap junction, longevity, ErbB, thyroid hormone, autophagy, and growth hormone signaling pathways (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">7c</xref>). Consistent with this possibility, early lithium treatment of Dyrk1a-KI mice reverses most (8 out of 10) of these pathways (insulin, cAMP, oxytocin, AMPK, gap junction, longevity, ErbB, and autophagy) (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5b</xref>) and rescues the brain-volume phenotypes at ~P21 (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4a</xref>). Interestingly, the rescued pathways have been implicated in regulating brain development and function, as well as in various brain disorders [<xref ref-type="bibr" rid="CR53">53</xref>&#x02013;<xref ref-type="bibr" rid="CR60">60</xref>]. A previous study using <italic>Dyrk1a</italic> deleted in Emx1-positive excitatory neurons implicated TrkB-BDNF, ERK/MAPK, and mTOR signaling pathways in the pathophysiology underlying the limited growth of cortical neurons [<xref ref-type="bibr" rid="CR20">20</xref>]. Another previous study has shown that two patient-derived <italic>Dyrk1a</italic>-truncating mutations (R205X and E239X) introduced by in utero electroporation can cause deficits in neuronal and synaptic development [<xref ref-type="bibr" rid="CR8">8</xref>]. Our study extends these findings by demonstrating that a patient derived mutation in <italic>Dyrk1a</italic>, which is expressed in various brain cell types, can cause lithium-responsive deficits in multiple signaling pathways in a spatiotemporal context better mimicking the patient condition.</p><p id="Par53">Our study suggests that a selective decrease in excitatory synaptic density (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2d&#x02013;g</xref>) may be a mechanism underlying the Dyrk1a-KI mouse phenotypes. In support of this possibility, early lithium treatment of Dyrk1a-KI mice rescues their synaptic, dendritic, brain size, and behavioral phenotypes (Figs.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref> and <xref rid="Fig4" ref-type="fig">4</xref>). A possible mechanism leading to the decrease in excitatory synapse density could be suppression of dendritic arborization (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3b</xref>, c), which may involve multiple signaling pathways enriched in the lithium-rescued ~P21 PTM-DEPPs (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5b</xref>). Dendritic arborization is regulated by multiple extracellular signals (i.e., neurotransmitters and neurotrophins) [<xref ref-type="bibr" rid="CR61">61</xref>] and signaling pathways, including the insulin [<xref ref-type="bibr" rid="CR62">62</xref>&#x02013;<xref ref-type="bibr" rid="CR64">64</xref>], AMPK [<xref ref-type="bibr" rid="CR65">65</xref>&#x02013;<xref ref-type="bibr" rid="CR67">67</xref>], gap junction [<xref ref-type="bibr" rid="CR68">68</xref>&#x02013;<xref ref-type="bibr" rid="CR70">70</xref>], and ErbB [<xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR71">71</xref>] pathways.</p><p id="Par54">Alternatively, the decreased excitatory synaptic density seen in Dyrk1a-KI mice could involve synaptic protein deficits and/or dendritic shrinkage. The ~P21 lithium-rescued PTM-DEPPs are enriched for synapse-related GO functions and SynGO proteins (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5b</xref>; Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">6b</xref>). A notable protein among the lithium-rescued synaptic proteins is Kalirin, a Rho-GEF that regulates synaptic function as well as dendritic arborization and are implicated in neurodevelopmental disorders (i.e., schizophrenia) [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]. Another is Elavl2, a member of the ELAVL family of RNA-binding proteins, which regulate posttranscriptional processes, such as neuronal mRNA stability and splicing [<xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR73">73</xref>], and are implicated in neural development and brain disorders [<xref ref-type="bibr" rid="CR74">74</xref>]. Elavl2 is the least studied member of the family, but it is known to localize to and regulate synapses [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>], and been implicated in neurodevelopment, synaptic regulation, and ASD [<xref ref-type="bibr" rid="CR75">75</xref>]. Our findings in the present study, particularly the phosphorylation-dependent regulation of dendritic arbors via Kalrn-S448 and Elavl2-S221 (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">11e, f</xref>), suggest that Dyrk1a-dependent/related phosphorylation may regulate Kalrn- and Elavl2-mediated dendritic growth and synaptic functions. This parallels the NMDA receptor activation-dependent phosphorylation of CaMKII and Kalirin-7 (at Thr95), which enhances Kalirin-7&#x02019;s Rho-GEF activity [<xref ref-type="bibr" rid="CR76">76</xref>] and hippocampal LTP [<xref ref-type="bibr" rid="CR77">77</xref>].</p><p id="Par55">Interestingly, early lithium treatment in Dyrk1a-KI mice is associated with somewhat different molecular effects in the short and long terms (&#x02009;~&#x02009;P21 and ~P60, respectively) (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>; Supplementary Figs.&#x000a0;<xref rid="MOESM1" ref-type="media">5</xref>&#x02013;<xref rid="MOESM1" ref-type="media">10</xref>). At ~P21, the early lithium treatment is seen to rescue multiple signaling pathways to normalize dendritic arborization and excitatory synaptic density. This signaling pathway-focus rescue effect is less pronounced at ~P60, when the effect appears to focus on synaptic proteins. It is possible that the rescue of signaling pathways at ~P21 may prevent the changes in synaptic proteins from appearing at ~P60. This is in line with the notion that early correction of key pathologies is important for long-lasting prevention of ASD-related phenotypes at later stages [<xref ref-type="bibr" rid="CR37">37</xref>].</p><p id="Par56">Lithium treatment is known to have multiple action mechanisms, including GSK3&#x003b2; inhibition. GSK3&#x003b2; exerts pleiotropic effects on neural development through the regulation of multiple signaling pathways, including the PI3K-Akt-mTOR pathway [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>] and &#x003b2;-catenin-dependent gene expression [<xref ref-type="bibr" rid="CR78">78</xref>]. In addition, GSK3&#x003b2; regulates excitatory synapses and dendritic spines through multiple mechanisms, including synaptic plasticity (i.e., LTD promotion and LTP suppression) [<xref ref-type="bibr" rid="CR31">31</xref>] and &#x003b2;-catenin degradation [<xref ref-type="bibr" rid="CR79">79</xref>]. Lithium also regulates neuronal and synaptic development and functions through various signaling pathways, including GSK3&#x003b2; and CREB [<xref ref-type="bibr" rid="CR80">80</xref>&#x02013;<xref ref-type="bibr" rid="CR84">84</xref>]. For example, lithium promotes the synaptic localization of the GluA2 AMPA receptor through &#x003b4;-catenin [<xref ref-type="bibr" rid="CR32">32</xref>]. In addition, Dyrk1a acts as a priming kinase for GSK3&#x003b2; in the phosphorylation of eIF2B&#x003b5; and tau [<xref ref-type="bibr" rid="CR85">85</xref>]. However, our analysis of GSK3&#x003b2; phosphorylation and its potential upstream kinases suggests that GSK3&#x003b2; inhibition may not be critical in the lithium-dependent rescue of Dyrk1a-KI phenotypes, and, instead, the data points to the importance of direct Dyrk1a substrates (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">11a&#x02013;d</xref>).</p><p id="Par57">Lithium, which is a gold-standard medication for bipolar disorder, was recently shown to be useful for neurological disorders [<xref ref-type="bibr" rid="CR33">33</xref>&#x02013;<xref ref-type="bibr" rid="CR36">36</xref>]. Our results, together with the recently reported beneficial effects of lithium in a Shank3-mutant mouse model of ASD [<xref ref-type="bibr" rid="CR86">86</xref>] and fragile X mouse models [<xref ref-type="bibr" rid="CR87">87</xref>], suggest that lithium could have therapeutic potential for ASD and related neurodevelopmental disorders.</p></sec><sec id="Sec22" sec-type="supplementary-material"><title>Supplementary information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41380_2024_2865_MOESM1_ESM.pdf"><caption><p>Supplementary Information</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="41380_2024_2865_MOESM2_ESM.xlsx"><caption><p>Supplementary Table 1</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="41380_2024_2865_MOESM3_ESM.xls"><caption><p>Supplementary Table 2</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="41380_2024_2865_MOESM4_ESM.xls"><caption><p>Supplementary Table 3</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM5"><media xlink:href="41380_2024_2865_MOESM5_ESM.xls"><caption><p>Supplementary Table 4</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM6"><media xlink:href="41380_2024_2865_MOESM6_ESM.xls"><caption><p>Supplementary Table 5</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM7"><media xlink:href="41380_2024_2865_MOESM7_ESM.xls"><caption><p>Supplementary Table 6</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM8"><media xlink:href="41380_2024_2865_MOESM8_ESM.xls"><caption><p>Supplementary Table 7</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>These authors contributed equally: Junyeop Daniel Roh, Mihyun Bae.</p></fn></fn-group><sec><title>Supplementary information</title><p>The online version contains supplementary material available at 10.1038/s41380-024-02865-2.</p></sec><ack><title>Acknowledgements</title><p>This research was supported by National Research Foundation grant (NRF Grant RS-2023-00272290 to H.K., 2022M3H9A2096186 to J.Y.K., and 2021R1A2C1007061 to Y.C.B.), Korea Basic Science Institute grant (C470000 to J.Y.K.) and IBS-R002-D1 to E.K.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>JDR designed the experiments and performed proteomic, electrophysiological, and behavioral experiments and helped write the manuscript. MB designed the experiments and performed proteomic, electrophysiological, and behavioral experiments and helped write the manuscript. HyosangK performed electrophysiological and behavioral experiments. YY performed total proteome and phosphoproteome analyses. YLee performed electrophysiological and behavioral experiments. YC performed electron microscopy experiments. SL performed cultured neuron experiments. YLi performed electrophysiological and behavioral experiments. EY performed in situ hybridization experiments. HJ performed total proteome and phosphoproteome analyses. HyeonjiK performed total proteome and phosphoproteome analyses. HyunK designed experiments and helped write the manuscript. HKang analyzed total proteome data and helped write the manuscript. JE performed MRI experiments. JPL designed experiments and helped write the manuscript. YCB designed experiments and helped write the manuscript. JYK designed experiments and helped write the manuscript. EK designed experiments and helped write the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open Access funding enabled and organized by KAIST.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>i) The RNA-Seq data for Dyrk1a-KI and WT mice at P21 and P60 have been deposited at the GEO (Gene Expression Omnibus) repository with accession GSE274730. ii) The raw MS data files for total and PTM proteomes from heterozygous Dyrk1a-KI and WT mice at P21 have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the identifier PXD053587 for total proteome analysis and the identifier PXD050102 for phosphoproteome analysis. iii) The raw MS data files for total and PTM proteomes from heterozygous Dyrk1a-KI and WT mice at P60 have been deposited to the repository MassIVE with the identifier PXD049356 for total proteome analysis and the identifier PXD049357 for phosphoproteome analysis. iv) The PTM data for P60 from homozygous Dyrk1a-KI and WT mice have been deposited to the ProteomeXchange database under the accession number of PXD050100.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par58">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>M</given-names></name><name><surname>Dhanasekaran</surname><given-names>AR</given-names></name><name><surname>Gardiner</surname><given-names>KJ</given-names></name></person-group><article-title>Mouse models of Down syndrome: gene content and consequences</article-title><source>Mamm Genome</source><year>2016</year><volume>27</volume><fpage>538</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1007/s00335-016-9661-8</pub-id><pub-id pub-id-type="pmid">27538963</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Gupta M, Dhanasekaran AR, Gardiner KJ. Mouse models of Down syndrome: gene content and consequences. Mamm Genome. 2016;27:538&#x02013;55.<pub-id pub-id-type="pmid">27538963</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Reeves</surname><given-names>RH</given-names></name><name><surname>Irving</surname><given-names>NG</given-names></name><name><surname>Moran</surname><given-names>TH</given-names></name><name><surname>Wohn</surname><given-names>A</given-names></name><name><surname>Kitt</surname><given-names>C</given-names></name><name><surname>Sisodia</surname><given-names>SS</given-names></name><etal/></person-group><article-title>A mouse model for Down syndrome exhibits learning and behaviour deficits</article-title><source>Nat Genet</source><year>1995</year><volume>11</volume><fpage>177</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1038/ng1095-177</pub-id><pub-id pub-id-type="pmid">7550346</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Reeves RH, Irving NG, Moran TH, Wohn A, Kitt C, Sisodia SS, et al. A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat Genet. 1995;11:177&#x02013;84.<pub-id pub-id-type="pmid">7550346</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Moyer</surname><given-names>AJ</given-names></name><name><surname>Gardiner</surname><given-names>K</given-names></name><name><surname>Reeves</surname><given-names>RH</given-names></name></person-group><article-title>All Creatures Great and Small: New Approaches for Understanding Down Syndrome Genetics</article-title><source>Trends Genet</source><year>2021</year><volume>37</volume><fpage>444</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.tig.2020.09.017</pub-id><pub-id pub-id-type="pmid">33097276</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Moyer AJ, Gardiner K, Reeves RH. All Creatures Great and Small: New Approaches for Understanding Down Syndrome Genetics. Trends Genet. 2021;37:444&#x02013;59.<pub-id pub-id-type="pmid">33097276</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Earl</surname><given-names>RK</given-names></name><name><surname>Turner</surname><given-names>TN</given-names></name><name><surname>Mefford</surname><given-names>HC</given-names></name><name><surname>Hudac</surname><given-names>CM</given-names></name><name><surname>Gerdts</surname><given-names>J</given-names></name><name><surname>Eichler</surname><given-names>EE</given-names></name><etal/></person-group><article-title>Clinical phenotype of ASD-associated DYRK1A haploinsufficiency</article-title><source>Mol Autism</source><year>2017</year><volume>8</volume><fpage>54</fpage><pub-id pub-id-type="doi">10.1186/s13229-017-0173-5</pub-id><pub-id pub-id-type="pmid">29034068</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Earl RK, Turner TN, Mefford HC, Hudac CM, Gerdts J, Eichler EE, et al. Clinical phenotype of ASD-associated DYRK1A haploinsufficiency. Mol Autism. 2017;8:54.<pub-id pub-id-type="pmid">29034068</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">van Bon BWM, Coe BP, de Vries BBA, Eichler EEDYRK1A Syndrome. In: Adam MP, Feldman J, et al. (eds). GeneReviews<italic>((R))</italic>: Seattle (WA), 1993.</mixed-citation></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>van Bon</surname><given-names>BW</given-names></name><name><surname>Coe</surname><given-names>BP</given-names></name><name><surname>Bernier</surname><given-names>R</given-names></name><name><surname>Green</surname><given-names>C</given-names></name><name><surname>Gerdts</surname><given-names>J</given-names></name><name><surname>Witherspoon</surname><given-names>K</given-names></name><etal/></person-group><article-title>Disruptive de novo mutations of DYRK1A lead to a syndromic form of autism and ID</article-title><source>Mol Psychiatry</source><year>2016</year><volume>21</volume><fpage>126</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1038/mp.2015.5</pub-id><pub-id pub-id-type="pmid">25707398</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">van Bon BW, Coe BP, Bernier R, Green C, Gerdts J, Witherspoon K, et al. Disruptive de novo mutations of DYRK1A lead to a syndromic form of autism and ID. Mol Psychiatry. 2016;21:126&#x02013;32.<pub-id pub-id-type="pmid">25707398</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Argiropoulos</surname><given-names>B</given-names></name><name><surname>Dorrani</surname><given-names>N</given-names></name><name><surname>Mann</surname><given-names>J</given-names></name><name><surname>Martinez-Agosto</surname><given-names>JA</given-names></name><etal/></person-group><article-title>DYRK1A haploinsufficiency causes a new recognizable syndrome with microcephaly, intellectual disability, speech impairment, and distinct facies</article-title><source>Eur J Hum Genet</source><year>2015</year><volume>23</volume><fpage>1473</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1038/ejhg.2015.71</pub-id><pub-id pub-id-type="pmid">25944381</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Ji J, Lee H, Argiropoulos B, Dorrani N, Mann J, Martinez-Agosto JA, et al. DYRK1A haploinsufficiency causes a new recognizable syndrome with microcephaly, intellectual disability, speech impairment, and distinct facies. Eur J Hum Genet. 2015;23:1473&#x02013;81.<pub-id pub-id-type="pmid">25944381</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Dang</surname><given-names>T</given-names></name><name><surname>Duan</surname><given-names>WY</given-names></name><name><surname>Yu</surname><given-names>B</given-names></name><name><surname>Tong</surname><given-names>DL</given-names></name><name><surname>Cheng</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>YF</given-names></name><etal/></person-group><article-title>Autism-associated Dyrk1a truncation mutants impair neuronal dendritic and spine growth and interfere with postnatal cortical development</article-title><source>Mol Psychiatry</source><year>2018</year><volume>23</volume><fpage>747</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1038/mp.2016.253</pub-id><pub-id pub-id-type="pmid">28167836</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Dang T, Duan WY, Yu B, Tong DL, Cheng C, Zhang YF, et al. Autism-associated Dyrk1a truncation mutants impair neuronal dendritic and spine growth and interfere with postnatal cortical development. Mol Psychiatry. 2018;23:747&#x02013;58.<pub-id pub-id-type="pmid">28167836</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Courcet</surname><given-names>JB</given-names></name><name><surname>Faivre</surname><given-names>L</given-names></name><name><surname>Malzac</surname><given-names>P</given-names></name><name><surname>Masurel-Paulet</surname><given-names>A</given-names></name><name><surname>Lopez</surname><given-names>E</given-names></name><name><surname>Callier</surname><given-names>P</given-names></name><etal/></person-group><article-title>The DYRK1A gene is a cause of syndromic intellectual disability with severe microcephaly and epilepsy</article-title><source>J Med Genet</source><year>2012</year><volume>49</volume><fpage>731</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1136/jmedgenet-2012-101251</pub-id><pub-id pub-id-type="pmid">23099646</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Courcet JB, Faivre L, Malzac P, Masurel-Paulet A, Lopez E, Callier P, et al. The DYRK1A gene is a cause of syndromic intellectual disability with severe microcephaly and epilepsy. J Med Genet. 2012;49:731&#x02013;6.<pub-id pub-id-type="pmid">23099646</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Roak</surname><given-names>BJ</given-names></name><name><surname>Vives</surname><given-names>L</given-names></name><name><surname>Fu</surname><given-names>W</given-names></name><name><surname>Egertson</surname><given-names>JD</given-names></name><name><surname>Stanaway</surname><given-names>IB</given-names></name><name><surname>Phelps</surname><given-names>IG</given-names></name><etal/></person-group><article-title>Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders</article-title><source>Science</source><year>2012</year><volume>338</volume><fpage>1619</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1126/science.1227764</pub-id><pub-id pub-id-type="pmid">23160955</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">O&#x02019;Roak BJ, Vives L, Fu W, Egertson JD, Stanaway IB, Phelps IG, et al. Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. Science. 2012;338:1619&#x02013;22.<pub-id pub-id-type="pmid">23160955</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><collab>Deciphering Developmental Disorders S.</collab></person-group><article-title>Large-scale discovery of novel genetic causes of developmental disorders</article-title><source>Nature</source><year>2015</year><volume>519</volume><fpage>223</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/nature14135</pub-id><pub-id pub-id-type="pmid">25533962</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Deciphering Developmental Disorders S. Large-scale discovery of novel genetic causes of developmental disorders. Nature. 2015;519:223&#x02013;8.<pub-id pub-id-type="pmid">25533962</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Kurtz-Nelson</surname><given-names>EC</given-names></name><name><surname>Rea</surname><given-names>HM</given-names></name><name><surname>Petriceks</surname><given-names>AC</given-names></name><name><surname>Hudac</surname><given-names>CM</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Earl</surname><given-names>RK</given-names></name><etal/></person-group><article-title>Characterizing the autism spectrum phenotype in DYRK1A-related syndrome</article-title><source>Autism Res</source><year>2023</year><volume>16</volume><fpage>1488</fpage><lpage>1500</lpage><pub-id pub-id-type="doi">10.1002/aur.2995</pub-id><pub-id pub-id-type="pmid">37497568</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Kurtz-Nelson EC, Rea HM, Petriceks AC, Hudac CM, Wang T, Earl RK, et al. Characterizing the autism spectrum phenotype in DYRK1A-related syndrome. Autism Res. 2023;16:1488&#x02013;1500.<pub-id pub-id-type="pmid">37497568</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><collab>Deciphering Developmental Disorders S.</collab></person-group><article-title>Prevalence and architecture of de novo mutations in developmental disorders</article-title><source>Nature</source><year>2017</year><volume>542</volume><fpage>433</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/nature21062</pub-id><pub-id pub-id-type="pmid">28135719</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Deciphering Developmental Disorders S. Prevalence and architecture of de novo mutations in developmental disorders. Nature. 2017;542:433&#x02013;8.<pub-id pub-id-type="pmid">28135719</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Fotaki</surname><given-names>V</given-names></name><name><surname>Dierssen</surname><given-names>M</given-names></name><name><surname>Alcantara</surname><given-names>S</given-names></name><name><surname>Martinez</surname><given-names>S</given-names></name><name><surname>Marti</surname><given-names>E</given-names></name><name><surname>Casas</surname><given-names>C</given-names></name><etal/></person-group><article-title>Dyrk1A haploinsufficiency affects viability and causes developmental delay and abnormal brain morphology in mice</article-title><source>Mol Cell Biol</source><year>2002</year><volume>22</volume><fpage>6636</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1128/MCB.22.18.6636-6647.2002</pub-id><pub-id pub-id-type="pmid">12192061</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Fotaki V, Dierssen M, Alcantara S, Martinez S, Marti E, Casas C, et al. Dyrk1A haploinsufficiency affects viability and causes developmental delay and abnormal brain morphology in mice. Mol Cell Biol. 2002;22:6636&#x02013;47.<pub-id pub-id-type="pmid">12192061</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Benavides-Piccione</surname><given-names>R</given-names></name><name><surname>Dierssen</surname><given-names>M</given-names></name><name><surname>Ballesteros-Yanez</surname><given-names>I</given-names></name><name><surname>Martinez de Lagran</surname><given-names>M</given-names></name><name><surname>Arbones</surname><given-names>ML</given-names></name><name><surname>Fotaki</surname><given-names>V</given-names></name><etal/></person-group><article-title>Alterations in the phenotype of neocortical pyramidal cells in the Dyrk1A+/- mouse</article-title><source>Neurobiol Dis</source><year>2005</year><volume>20</volume><fpage>115</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2005.02.004</pub-id><pub-id pub-id-type="pmid">16137572</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Benavides-Piccione R, Dierssen M, Ballesteros-Yanez I, Martinez de Lagran M, Arbones ML, Fotaki V, et al. Alterations in the phenotype of neocortical pyramidal cells in the Dyrk1A+/- mouse. Neurobiol Dis. 2005;20:115&#x02013;22.<pub-id pub-id-type="pmid">16137572</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Raveau</surname><given-names>M</given-names></name><name><surname>Shimohata</surname><given-names>A</given-names></name><name><surname>Amano</surname><given-names>K</given-names></name><name><surname>Miyamoto</surname><given-names>H</given-names></name><name><surname>Yamakawa</surname><given-names>K</given-names></name></person-group><article-title>DYRK1A-haploinsufficiency in mice causes autistic-like features and febrile seizures</article-title><source>Neurobiol Dis</source><year>2018</year><volume>110</volume><fpage>180</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2017.12.003</pub-id><pub-id pub-id-type="pmid">29223763</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Raveau M, Shimohata A, Amano K, Miyamoto H, Yamakawa K. DYRK1A-haploinsufficiency in mice causes autistic-like features and febrile seizures. Neurobiol Dis. 2018;110:180&#x02013;91.<pub-id pub-id-type="pmid">29223763</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Arranz</surname><given-names>J</given-names></name><name><surname>Balducci</surname><given-names>E</given-names></name><name><surname>Arato</surname><given-names>K</given-names></name><name><surname>Sanchez-Elexpuru</surname><given-names>G</given-names></name><name><surname>Najas</surname><given-names>S</given-names></name><name><surname>Parras</surname><given-names>A</given-names></name><etal/></person-group><article-title>Impaired development of neocortical circuits contributes to the neurological alterations in DYRK1A haploinsufficiency syndrome</article-title><source>Neurobiol Dis</source><year>2019</year><volume>127</volume><fpage>210</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2019.02.022</pub-id><pub-id pub-id-type="pmid">30831192</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Arranz J, Balducci E, Arato K, Sanchez-Elexpuru G, Najas S, Parras A, et al. Impaired development of neocortical circuits contributes to the neurological alterations in DYRK1A haploinsufficiency syndrome. Neurobiol Dis. 2019;127:210&#x02013;22.<pub-id pub-id-type="pmid">30831192</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Pijuan</surname><given-names>I</given-names></name><name><surname>Balducci</surname><given-names>E</given-names></name><name><surname>Soto-Sanchez</surname><given-names>C</given-names></name><name><surname>Fernandez</surname><given-names>E</given-names></name><name><surname>Barallobre</surname><given-names>MJ</given-names></name><name><surname>Arbones</surname><given-names>ML</given-names></name></person-group><article-title>Impaired macroglial development and axonal conductivity contributes to the neuropathology of DYRK1A-related intellectual disability syndrome</article-title><source>Sci Rep</source><year>2022</year><volume>12</volume><fpage>19912</fpage><pub-id pub-id-type="doi">10.1038/s41598-022-24284-5</pub-id><pub-id pub-id-type="pmid">36402907</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Pijuan I, Balducci E, Soto-Sanchez C, Fernandez E, Barallobre MJ, Arbones ML. Impaired macroglial development and axonal conductivity contributes to the neuropathology of DYRK1A-related intellectual disability syndrome. Sci Rep. 2022;12:19912.<pub-id pub-id-type="pmid">36402907</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Fotaki</surname><given-names>V</given-names></name><name><surname>Martinez De Lagran</surname><given-names>M</given-names></name><name><surname>Estivill</surname><given-names>X</given-names></name><name><surname>Arbones</surname><given-names>M</given-names></name><name><surname>Dierssen</surname><given-names>M</given-names></name></person-group><article-title>Haploinsufficiency of Dyrk1A in mice leads to specific alterations in the development and regulation of motor activity</article-title><source>Behav Neurosci</source><year>2004</year><volume>118</volume><fpage>815</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1037/0735-7044.118.4.815</pub-id><pub-id pub-id-type="pmid">15301607</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Fotaki V, Martinez De Lagran M, Estivill X, Arbones M, Dierssen M. Haploinsufficiency of Dyrk1A in mice leads to specific alterations in the development and regulation of motor activity. Behav Neurosci. 2004;118:815&#x02013;21.<pub-id pub-id-type="pmid">15301607</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>JA</given-names></name><name><surname>LaFlamme</surname><given-names>CW</given-names></name><name><surname>Tsaprailis</surname><given-names>G</given-names></name><name><surname>Crynen</surname><given-names>G</given-names></name><name><surname>Page</surname><given-names>DT</given-names></name></person-group><article-title>Dyrk1a Mutations Cause Undergrowth of Cortical Pyramidal Neurons via Dysregulated Growth Factor Signaling</article-title><source>Biol Psychiatry</source><year>2021</year><volume>90</volume><fpage>295</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2021.01.012</pub-id><pub-id pub-id-type="pmid">33840455</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Levy JA, LaFlamme CW, Tsaprailis G, Crynen G, Page DT. Dyrk1a Mutations Cause Undergrowth of Cortical Pyramidal Neurons via Dysregulated Growth Factor Signaling. Biol Psychiatry. 2021;90:295&#x02013;306.<pub-id pub-id-type="pmid">33840455</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>I</given-names></name><name><surname>Manno</surname><given-names>FAM</given-names></name><name><surname>Manno</surname><given-names>SHC</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Lau</surname><given-names>C</given-names></name></person-group><article-title>Detection of lithium in breast milk and in situ elemental analysis of the mammary gland</article-title><source>Biomed Opt Express</source><year>2018</year><volume>9</volume><fpage>4184</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1364/BOE.9.004184</pub-id><pub-id pub-id-type="pmid">30615726</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Ahmed I, Manno FAM, Manno SHC, Liu Y, Zhang Y, Lau C. Detection of lithium in breast milk and in situ elemental analysis of the mammary gland. Biomed Opt Express. 2018;9:4184&#x02013;95.<pub-id pub-id-type="pmid">30615726</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Chiou</surname><given-names>SY</given-names></name><name><surname>Kysenius</surname><given-names>K</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Habgood</surname><given-names>MD</given-names></name><name><surname>Koehn</surname><given-names>LM</given-names></name><name><surname>Qiu</surname><given-names>F</given-names></name><etal/></person-group><article-title>Lithium administered to pregnant, lactating and neonatal rats: entry into developing brain</article-title><source>Fluids Barriers CNS</source><year>2021</year><volume>18</volume><fpage>57</fpage><pub-id pub-id-type="doi">10.1186/s12987-021-00285-w</pub-id><pub-id pub-id-type="pmid">34876168</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Chiou SY, Kysenius K, Huang Y, Habgood MD, Koehn LM, Qiu F, et al. Lithium administered to pregnant, lactating and neonatal rats: entry into developing brain. Fluids Barriers CNS. 2021;18:57.<pub-id pub-id-type="pmid">34876168</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>McLaughlin</surname><given-names>CR</given-names></name><name><surname>Cramer</surname><given-names>CP</given-names></name></person-group><article-title>Acute administration of lithium carbonate interferes with suckling in neonatal rats</article-title><source>Pharmacol Biochem Behav</source><year>1989</year><volume>32</volume><fpage>453</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/0091-3057(89)90178-0</pub-id><pub-id pub-id-type="pmid">2498909</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">McLaughlin CR, Cramer CP. Acute administration of lithium carbonate interferes with suckling in neonatal rats. Pharmacol Biochem Behav. 1989;32:453&#x02013;8.<pub-id pub-id-type="pmid">2498909</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>WJ</given-names></name><name><surname>Sternberg</surname><given-names>LR</given-names></name><name><surname>Kasten-Sportes</surname><given-names>C</given-names></name><name><surname>Keuren</surname><given-names>ML</given-names></name><name><surname>Chung</surname><given-names>SH</given-names></name><name><surname>Slack</surname><given-names>AC</given-names></name><etal/></person-group><article-title>Isolation of human and murine homologues of the Drosophila minibrain gene: human homologue maps to 21q22.2 in the Down syndrome &#x0201c;critical region</article-title><source>Genomics</source><year>1996</year><volume>38</volume><fpage>331</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1006/geno.1996.0636</pub-id><pub-id pub-id-type="pmid">8975710</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Song WJ, Sternberg LR, Kasten-Sportes C, Keuren ML, Chung SH, Slack AC, et al. Isolation of human and murine homologues of the Drosophila minibrain gene: human homologue maps to 21q22.2 in the Down syndrome &#x0201c;critical region. Genomics. 1996;38:331&#x02013;9.<pub-id pub-id-type="pmid">8975710</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Guimera</surname><given-names>J</given-names></name><name><surname>Casas</surname><given-names>C</given-names></name><name><surname>Pucharcos</surname><given-names>C</given-names></name><name><surname>Solans</surname><given-names>A</given-names></name><name><surname>Domenech</surname><given-names>A</given-names></name><name><surname>Planas</surname><given-names>AM</given-names></name><etal/></person-group><article-title>A human homologue of Drosophila minibrain (MNB) is expressed in the neuronal regions affected in Down syndrome and maps to the critical region</article-title><source>Hum Mol Genet</source><year>1996</year><volume>5</volume><fpage>1305</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1093/hmg/5.9.1305</pub-id><pub-id pub-id-type="pmid">8872470</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Guimera J, Casas C, Pucharcos C, Solans A, Domenech A, Planas AM, et al. A human homologue of Drosophila minibrain (MNB) is expressed in the neuronal regions affected in Down syndrome and maps to the critical region. Hum Mol Genet. 1996;5:1305&#x02013;10.<pub-id pub-id-type="pmid">8872470</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Sohal</surname><given-names>VS</given-names></name><name><surname>Rubenstein</surname><given-names>JLR</given-names></name></person-group><article-title>Excitation-inhibition balance as a framework for investigating mechanisms in neuropsychiatric disorders</article-title><source>Mol Psychiatry</source><year>2019</year><volume>24</volume><fpage>1248</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1038/s41380-019-0426-0</pub-id><pub-id pub-id-type="pmid">31089192</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Sohal VS, Rubenstein JLR. Excitation-inhibition balance as a framework for investigating mechanisms in neuropsychiatric disorders. Mol Psychiatry. 2019;24:1248&#x02013;57.<pub-id pub-id-type="pmid">31089192</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>E</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>E</given-names></name></person-group><article-title>Excitation/Inhibition Imbalance in Animal Models of Autism Spectrum Disorders</article-title><source>Biol Psychiatry</source><year>2017</year><volume>81</volume><fpage>838</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2016.05.011</pub-id><pub-id pub-id-type="pmid">27450033</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Lee E, Lee J, Kim E. Excitation/Inhibition Imbalance in Animal Models of Autism Spectrum Disorders. Biol Psychiatry. 2017;81:838&#x02013;47.<pub-id pub-id-type="pmid">27450033</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>SB</given-names></name><name><surname>Valakh</surname><given-names>V</given-names></name></person-group><article-title>Excitatory/Inhibitory Balance and Circuit Homeostasis in Autism Spectrum Disorders</article-title><source>Neuron</source><year>2015</year><volume>87</volume><fpage>684</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2015.07.033</pub-id><pub-id pub-id-type="pmid">26291155</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Nelson SB, Valakh V. Excitatory/Inhibitory Balance and Circuit Homeostasis in Autism Spectrum Disorders. Neuron. 2015;87:684&#x02013;98.<pub-id pub-id-type="pmid">26291155</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Hur</surname><given-names>EM</given-names></name><name><surname>Zhou</surname><given-names>FQ</given-names></name></person-group><article-title>GSK3 signalling in neural development</article-title><source>Nat Rev Neurosci</source><year>2010</year><volume>11</volume><fpage>539</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1038/nrn2870</pub-id><pub-id pub-id-type="pmid">20648061</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Hur EM, Zhou FQ. GSK3 signalling in neural development. Nat Rev Neurosci. 2010;11:539&#x02013;51.<pub-id pub-id-type="pmid">20648061</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>WY</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Doble</surname><given-names>BW</given-names></name><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Woodgett</surname><given-names>JR</given-names></name><etal/></person-group><article-title>GSK-3 is a master regulator of neural progenitor homeostasis</article-title><source>Nat Neurosci</source><year>2009</year><volume>12</volume><fpage>1390</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1038/nn.2408</pub-id><pub-id pub-id-type="pmid">19801986</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Kim WY, Wang X, Wu Y, Doble BW, Patel S, Woodgett JR, et al. GSK-3 is a master regulator of neural progenitor homeostasis. Nat Neurosci. 2009;12:1390&#x02013;7.<pub-id pub-id-type="pmid">19801986</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Bradley</surname><given-names>CA</given-names></name><name><surname>Peineau</surname><given-names>S</given-names></name><name><surname>Taghibiglou</surname><given-names>C</given-names></name><name><surname>Nicolas</surname><given-names>CS</given-names></name><name><surname>Whitcomb</surname><given-names>DJ</given-names></name><name><surname>Bortolotto</surname><given-names>ZA</given-names></name><etal/></person-group><article-title>A pivotal role of GSK-3 in synaptic plasticity</article-title><source>Front Mol Neurosci</source><year>2012</year><volume>5</volume><fpage>13</fpage><pub-id pub-id-type="doi">10.3389/fnmol.2012.00013</pub-id><pub-id pub-id-type="pmid">22363262</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Bradley CA, Peineau S, Taghibiglou C, Nicolas CS, Whitcomb DJ, Bortolotto ZA, et al. A pivotal role of GSK-3 in synaptic plasticity. Front Mol Neurosci. 2012;5:13.<pub-id pub-id-type="pmid">22363262</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Farooq</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Khatri</surname><given-names>L</given-names></name><name><surname>Hikima</surname><given-names>T</given-names></name><name><surname>Rice</surname><given-names>ME</given-names></name><etal/></person-group><article-title>Lithium increases synaptic GluA2 in hippocampal neurons by elevating the delta-catenin protein</article-title><source>Neuropharmacology</source><year>2017</year><volume>113</volume><fpage>426</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2016.10.025</pub-id><pub-id pub-id-type="pmid">27793771</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Farooq M, Kim S, Patel S, Khatri L, Hikima T, Rice ME, et al. Lithium increases synaptic GluA2 in hippocampal neurons by elevating the delta-catenin protein. Neuropharmacology. 2017;113:426&#x02013;33.<pub-id pub-id-type="pmid">27793771</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Haupt</surname><given-names>M</given-names></name><name><surname>Bahr</surname><given-names>M</given-names></name><name><surname>Doeppner</surname><given-names>TR</given-names></name></person-group><article-title>Lithium beyond psychiatric indications: the reincarnation of a new old drug</article-title><source>Neural Regen Res</source><year>2021</year><volume>16</volume><fpage>2383</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.4103/1673-5374.313015</pub-id><pub-id pub-id-type="pmid">33907010</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Haupt M, Bahr M, Doeppner TR. Lithium beyond psychiatric indications: the reincarnation of a new old drug. Neural Regen Res. 2021;16:2383&#x02013;7.<pub-id pub-id-type="pmid">33907010</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Pagani</surname><given-names>R</given-names></name><name><surname>Gasparini</surname><given-names>A</given-names></name><name><surname>Ielmini</surname><given-names>M</given-names></name><name><surname>Caselli</surname><given-names>I</given-names></name><name><surname>Poloni</surname><given-names>N</given-names></name><name><surname>Ferrari</surname><given-names>M</given-names></name><etal/></person-group><article-title>Twenty years of Lithium pharmacogenetics: A systematic review</article-title><source>Psychiatry Res</source><year>2019</year><volume>278</volume><fpage>42</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.psychres.2019.05.036</pub-id><pub-id pub-id-type="pmid">31146140</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Pagani R, Gasparini A, Ielmini M, Caselli I, Poloni N, Ferrari M, et al. Twenty years of Lithium pharmacogenetics: A systematic review. Psychiatry Res. 2019;278:42&#x02013;50.<pub-id pub-id-type="pmid">31146140</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Leeds</surname><given-names>PR</given-names></name><name><surname>Yu</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Chiu</surname><given-names>CT</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Leng</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A new avenue for lithium: intervention in traumatic brain injury</article-title><source>ACS Chem Neurosci</source><year>2014</year><volume>5</volume><fpage>422</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1021/cn500040g</pub-id><pub-id pub-id-type="pmid">24697257</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Leeds PR, Yu F, Wang Z, Chiu CT, Zhang Y, Leng Y, et al. A new avenue for lithium: intervention in traumatic brain injury. ACS Chem Neurosci. 2014;5:422&#x02013;33.<pub-id pub-id-type="pmid">24697257</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Puglisi-Allegra</surname><given-names>S</given-names></name><name><surname>Ruggieri</surname><given-names>S</given-names></name><name><surname>Fornai</surname><given-names>F</given-names></name></person-group><article-title>Translational evidence for lithium-induced brain plasticity and neuroprotection in the treatment of neuropsychiatric disorders</article-title><source>Transl Psychiatry</source><year>2021</year><volume>11</volume><fpage>366</fpage><pub-id pub-id-type="doi">10.1038/s41398-021-01492-7</pub-id><pub-id pub-id-type="pmid">34226487</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Puglisi-Allegra S, Ruggieri S, Fornai F. Translational evidence for lithium-induced brain plasticity and neuroprotection in the treatment of neuropsychiatric disorders. Transl Psychiatry. 2021;11:366.<pub-id pub-id-type="pmid">34226487</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="other">Chung C, Shin W, Kim E Early and late corrections in mouse models of autism spectrum disorders. Biol Psychiatry 2021;in press.</mixed-citation></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Gillette</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>Proc Natl Acad Sci USA</source><year>2005</year><volume>102</volume><fpage>15545</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id><pub-id pub-id-type="pmid">16199517</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545&#x02013;50.<pub-id pub-id-type="pmid">16199517</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Merico</surname><given-names>D</given-names></name><name><surname>Isserlin</surname><given-names>R</given-names></name><name><surname>Stueker</surname><given-names>O</given-names></name><name><surname>Emili</surname><given-names>A</given-names></name><name><surname>Bader</surname><given-names>GD</given-names></name></person-group><article-title>Enrichment map: a network-based method for gene-set enrichment visualization and interpretation</article-title><source>PLoS One</source><year>2010</year><volume>5</volume><fpage>e13984</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0013984</pub-id><pub-id pub-id-type="pmid">21085593</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Merico D, Isserlin R, Stueker O, Emili A, Bader GD. Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS One. 2010;5:e13984.<pub-id pub-id-type="pmid">21085593</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Deribe</surname><given-names>YL</given-names></name><name><surname>Pawson</surname><given-names>T</given-names></name><name><surname>Dikic</surname><given-names>I</given-names></name></person-group><article-title>Post-translational modifications in signal integration</article-title><source>Nat Struct Mol Biol</source><year>2010</year><volume>17</volume><fpage>666</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1038/nsmb.1842</pub-id><pub-id pub-id-type="pmid">20495563</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Deribe YL, Pawson T, Dikic I. Post-translational modifications in signal integration. Nat Struct Mol Biol. 2010;17:666&#x02013;72.<pub-id pub-id-type="pmid">20495563</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Prabakaran</surname><given-names>S</given-names></name><name><surname>Lippens</surname><given-names>G</given-names></name><name><surname>Steen</surname><given-names>H</given-names></name><name><surname>Gunawardena</surname><given-names>J</given-names></name></person-group><article-title>Post-translational modification: nature&#x02019;s escape from genetic imprisonment and the basis for dynamic information encoding</article-title><source>Wiley Interdiscip Rev Syst Biol Med</source><year>2012</year><volume>4</volume><fpage>565</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1002/wsbm.1185</pub-id><pub-id pub-id-type="pmid">22899623</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Prabakaran S, Lippens G, Steen H, Gunawardena J. Post-translational modification: nature&#x02019;s escape from genetic imprisonment and the basis for dynamic information encoding. Wiley Interdiscip Rev Syst Biol Med. 2012;4:565&#x02013;83.<pub-id pub-id-type="pmid">22899623</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Koopmans</surname><given-names>F</given-names></name><name><surname>van Nierop</surname><given-names>P</given-names></name><name><surname>Andres-Alonso</surname><given-names>M</given-names></name><name><surname>Byrnes</surname><given-names>A</given-names></name><name><surname>Cijsouw</surname><given-names>T</given-names></name><name><surname>Coba</surname><given-names>MP</given-names></name><etal/></person-group><article-title>SynGO: An Evidence-Based, Expert-Curated Knowledge Base for the Synapse</article-title><source>Neuron</source><year>2019</year><volume>103</volume><fpage>217</fpage><lpage>34 e214</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2019.05.002</pub-id><pub-id pub-id-type="pmid">31171447</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Koopmans F, van Nierop P, Andres-Alonso M, Byrnes A, Cijsouw T, Coba MP, et al. SynGO: An Evidence-Based, Expert-Curated Knowledge Base for the Synapse. Neuron. 2019;103:217&#x02013;34 e214.<pub-id pub-id-type="pmid">31171447</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Kanehisa</surname><given-names>M</given-names></name><name><surname>Sato</surname><given-names>Y</given-names></name></person-group><article-title>KEGG Mapper for inferring cellular functions from protein sequences</article-title><source>Protein Sci</source><year>2020</year><volume>29</volume><fpage>28</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1002/pro.3711</pub-id><pub-id pub-id-type="pmid">31423653</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Kanehisa M, Sato Y. KEGG Mapper for inferring cellular functions from protein sequences. Protein Sci. 2020;29:28&#x02013;35.<pub-id pub-id-type="pmid">31423653</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Gene</surname><given-names>OntologyC</given-names></name></person-group><article-title>The Gene Ontology resource: enriching a GOld mine</article-title><source>Nucleic Acids Res</source><year>2021</year><volume>49</volume><fpage>D325</fpage><lpage>D334</lpage><pub-id pub-id-type="doi">10.1093/nar/gkaa1113</pub-id><pub-id pub-id-type="pmid">33290552</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Gene OntologyC. The Gene Ontology resource: enriching a GOld mine. Nucleic Acids Res. 2021;49:D325&#x02013;D334.<pub-id pub-id-type="pmid">33290552</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Bayes</surname><given-names>A</given-names></name><name><surname>Collins</surname><given-names>MO</given-names></name><name><surname>Reig-Viader</surname><given-names>R</given-names></name><name><surname>Gou</surname><given-names>G</given-names></name><name><surname>Goulding</surname><given-names>D</given-names></name><name><surname>Izquierdo</surname><given-names>A</given-names></name><etal/></person-group><article-title>Evolution of complexity in the zebrafish synapse proteome</article-title><source>Nat Commun</source><year>2017</year><volume>8</volume><fpage>14613</fpage><pub-id pub-id-type="doi">10.1038/ncomms14613</pub-id><pub-id pub-id-type="pmid">28252024</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Bayes A, Collins MO, Reig-Viader R, Gou G, Goulding D, Izquierdo A, et al. Evolution of complexity in the zebrafish synapse proteome. Nat Commun. 2017;8:14613.<pub-id pub-id-type="pmid">28252024</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Hemberg</surname><given-names>M</given-names></name><name><surname>Yoshida</surname><given-names>T</given-names></name><name><surname>Cho</surname><given-names>HY</given-names></name><name><surname>Murphy</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Promoter decommissioning by the NuRD chromatin remodeling complex triggers synaptic connectivity in the mammalian brain</article-title><source>Neuron</source><year>2014</year><volume>83</volume><fpage>122</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2014.05.039</pub-id><pub-id pub-id-type="pmid">24991957</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Yamada T, Yang Y, Hemberg M, Yoshida T, Cho HY, Murphy JP, et al. Promoter decommissioning by the NuRD chromatin remodeling complex triggers synaptic connectivity in the mammalian brain. Neuron. 2014;83:122&#x02013;34.<pub-id pub-id-type="pmid">24991957</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Alizzi</surname><given-names>RA</given-names></name><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Tenenbaum</surname><given-names>CM</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Gavis</surname><given-names>ER</given-names></name></person-group><article-title>The ELAV/Hu protein Found in neurons regulates cytoskeletal and ECM adhesion inputs for space-filling dendrite growth</article-title><source>PLoS Genet</source><year>2020</year><volume>16</volume><fpage>e1009235</fpage><pub-id pub-id-type="doi">10.1371/journal.pgen.1009235</pub-id><pub-id pub-id-type="pmid">33370772</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Alizzi RA, Xu D, Tenenbaum CM, Wang W, Gavis ER. The ELAV/Hu protein Found in neurons regulates cytoskeletal and ECM adhesion inputs for space-filling dendrite growth. PLoS Genet. 2020;16:e1009235.<pub-id pub-id-type="pmid">33370772</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Parnell</surname><given-names>E</given-names></name><name><surname>Shapiro</surname><given-names>LP</given-names></name><name><surname>Voorn</surname><given-names>RA</given-names></name><name><surname>Forrest</surname><given-names>MP</given-names></name><name><surname>Jalloul</surname><given-names>HA</given-names></name><name><surname>Loizzo</surname><given-names>DD</given-names></name><etal/></person-group><article-title>KALRN: A central regulator of synaptic function and synaptopathies</article-title><source>Gene</source><year>2021</year><volume>768</volume><fpage>145306</fpage><pub-id pub-id-type="doi">10.1016/j.gene.2020.145306</pub-id><pub-id pub-id-type="pmid">33189799</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Parnell E, Shapiro LP, Voorn RA, Forrest MP, Jalloul HA, Loizzo DD, et al. KALRN: A central regulator of synaptic function and synaptopathies. Gene. 2021;768:145306.<pub-id pub-id-type="pmid">33189799</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Penzes</surname><given-names>P</given-names></name><name><surname>Johnson</surname><given-names>RC</given-names></name><name><surname>Sattler</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Huganir</surname><given-names>RL</given-names></name><name><surname>Kambampati</surname><given-names>V</given-names></name><etal/></person-group><article-title>The neuronal Rho-GEF Kalirin-7 interacts with PDZ domain-containing proteins and regulates dendritic morphogenesis</article-title><source>Neuron</source><year>2001</year><volume>29</volume><fpage>229</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/S0896-6273(01)00193-3</pub-id><pub-id pub-id-type="pmid">11182094</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Penzes P, Johnson RC, Sattler R, Zhang X, Huganir RL, Kambampati V, et al. The neuronal Rho-GEF Kalirin-7 interacts with PDZ domain-containing proteins and regulates dendritic morphogenesis. Neuron. 2001;29:229&#x02013;42.<pub-id pub-id-type="pmid">11182094</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Beurel</surname><given-names>E</given-names></name><name><surname>Grieco</surname><given-names>SF</given-names></name><name><surname>Jope</surname><given-names>RS</given-names></name></person-group><article-title>Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases</article-title><source>Pharmacol Ther</source><year>2015</year><volume>148</volume><fpage>114</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2014.11.016</pub-id><pub-id pub-id-type="pmid">25435019</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Beurel E, Grieco SF, Jope RS. Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol Ther. 2015;148:114&#x02013;31.<pub-id pub-id-type="pmid">25435019</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Yaron-Barir</surname><given-names>TM</given-names></name><name><surname>Joughin</surname><given-names>BA</given-names></name><name><surname>Huntsman</surname><given-names>EM</given-names></name><name><surname>Kerelsky</surname><given-names>A</given-names></name><name><surname>Cizin</surname><given-names>DM</given-names></name><name><surname>Cohen</surname><given-names>BM</given-names></name><etal/></person-group><article-title>The intrinsic substrate specificity of the human tyrosine kinome</article-title><source>Nature</source><year>2024</year><volume>629</volume><fpage>1174</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1038/s41586-024-07407-y</pub-id><pub-id pub-id-type="pmid">38720073</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Yaron-Barir TM, Joughin BA, Huntsman EM, Kerelsky A, Cizin DM, Cohen BM, et al. The intrinsic substrate specificity of the human tyrosine kinome. Nature. 2024;629:1174&#x02013;81.<pub-id pub-id-type="pmid">38720073</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>JL</given-names></name><name><surname>Yaron</surname><given-names>TM</given-names></name><name><surname>Huntsman</surname><given-names>EM</given-names></name><name><surname>Kerelsky</surname><given-names>A</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name><etal/></person-group><article-title>An atlas of substrate specificities for the human serine/threonine kinome</article-title><source>Nature</source><year>2023</year><volume>613</volume><fpage>759</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-05575-3</pub-id><pub-id pub-id-type="pmid">36631611</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Johnson JL, Yaron TM, Huntsman EM, Kerelsky A, Song J, Regev A, et al. An atlas of substrate specificities for the human serine/threonine kinome. Nature. 2023;613:759&#x02013;66.<pub-id pub-id-type="pmid">36631611</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Banks</surname><given-names>WA</given-names></name><name><surname>Owen</surname><given-names>JB</given-names></name><name><surname>Erickson</surname><given-names>MA</given-names></name></person-group><article-title>Insulin in the brain: there and back again</article-title><source>Pharmacol Ther</source><year>2012</year><volume>136</volume><fpage>82</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2012.07.006</pub-id><pub-id pub-id-type="pmid">22820012</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Banks WA, Owen JB, Erickson MA. Insulin in the brain: there and back again. Pharmacol Ther. 2012;136:82&#x02013;93.<pub-id pub-id-type="pmid">22820012</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Scherer</surname><given-names>T</given-names></name><name><surname>Sakamoto</surname><given-names>K</given-names></name><name><surname>Buettner</surname><given-names>C</given-names></name></person-group><article-title>Brain insulin signalling in metabolic homeostasis and disease</article-title><source>Nat Rev Endocrinol</source><year>2021</year><volume>17</volume><fpage>468</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1038/s41574-021-00498-x</pub-id><pub-id pub-id-type="pmid">34108679</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Scherer T, Sakamoto K, Buettner C. Brain insulin signalling in metabolic homeostasis and disease. Nat Rev Endocrinol. 2021;17:468&#x02013;83.<pub-id pub-id-type="pmid">34108679</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Garza-Lombo</surname><given-names>C</given-names></name><name><surname>Schroder</surname><given-names>A</given-names></name><name><surname>Reyes-Reyes</surname><given-names>EM</given-names></name><name><surname>Franco</surname><given-names>R</given-names></name></person-group><article-title>mTOR/AMPK signaling in the brain: Cell metabolism, proteostasis and survival</article-title><source>Curr Opin Toxicol</source><year>2018</year><volume>8</volume><fpage>102</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.cotox.2018.05.002</pub-id><pub-id pub-id-type="pmid">30417160</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Garza-Lombo C, Schroder A, Reyes-Reyes EM, Franco R. mTOR/AMPK signaling in the brain: Cell metabolism, proteostasis and survival. Curr Opin Toxicol. 2018;8:102&#x02013;10.<pub-id pub-id-type="pmid">30417160</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Kataria</surname><given-names>H</given-names></name><name><surname>Alizadeh</surname><given-names>A</given-names></name><name><surname>Karimi-Abdolrezaee</surname><given-names>S</given-names></name></person-group><article-title>Neuregulin-1/ErbB network: An emerging modulator of nervous system injury and repair</article-title><source>Prog Neurobiol</source><year>2019</year><volume>180</volume><fpage>101643</fpage><pub-id pub-id-type="doi">10.1016/j.pneurobio.2019.101643</pub-id><pub-id pub-id-type="pmid">31229498</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Kataria H, Alizadeh A, Karimi-Abdolrezaee S. Neuregulin-1/ErbB network: An emerging modulator of nervous system injury and repair. Prog Neurobiol. 2019;180:101643.<pub-id pub-id-type="pmid">31229498</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Pitcher</surname><given-names>JL</given-names></name><name><surname>Alexander</surname><given-names>N</given-names></name><name><surname>Miranda</surname><given-names>PJ</given-names></name><name><surname>Johns</surname><given-names>TG</given-names></name></person-group><article-title>ErbB4 in the brain: Focus on high grade glioma</article-title><source>Front Oncol</source><year>2022</year><volume>12</volume><fpage>983514</fpage><pub-id pub-id-type="doi">10.3389/fonc.2022.983514</pub-id><pub-id pub-id-type="pmid">36119496</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Pitcher JL, Alexander N, Miranda PJ, Johns TG. ErbB4 in the brain: Focus on high grade glioma. Front Oncol. 2022;12:983514.<pub-id pub-id-type="pmid">36119496</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Grinevich</surname><given-names>V</given-names></name><name><surname>Neumann</surname><given-names>ID</given-names></name></person-group><article-title>Brain oxytocin: how puzzle stones from animal studies translate into psychiatry</article-title><source>Mol Psychiatry</source><year>2021</year><volume>26</volume><fpage>265</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1038/s41380-020-0802-9</pub-id><pub-id pub-id-type="pmid">32514104</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Grinevich V, Neumann ID. Brain oxytocin: how puzzle stones from animal studies translate into psychiatry. Mol Psychiatry. 2021;26:265&#x02013;79.<pub-id pub-id-type="pmid">32514104</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Coulon</surname><given-names>P</given-names></name><name><surname>Landisman</surname><given-names>CE</given-names></name></person-group><article-title>The Potential Role of Gap Junctional Plasticity in the Regulation of State</article-title><source>Neuron</source><year>2017</year><volume>93</volume><fpage>1275</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2017.02.041</pub-id><pub-id pub-id-type="pmid">28334604</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Coulon P, Landisman CE. The Potential Role of Gap Junctional Plasticity in the Regulation of State. Neuron. 2017;93:1275&#x02013;95.<pub-id pub-id-type="pmid">28334604</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Wyss-Coray</surname><given-names>T</given-names></name></person-group><article-title>Ageing, neurodegeneration and brain rejuvenation</article-title><source>Nature</source><year>2016</year><volume>539</volume><fpage>180</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1038/nature20411</pub-id><pub-id pub-id-type="pmid">27830812</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Wyss-Coray T. Ageing, neurodegeneration and brain rejuvenation. Nature. 2016;539:180&#x02013;6.<pub-id pub-id-type="pmid">27830812</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Hamad</surname><given-names>MIK</given-names></name><name><surname>Emerald</surname><given-names>BS</given-names></name><name><surname>Kumar</surname><given-names>KK</given-names></name><name><surname>Ibrahim</surname><given-names>MF</given-names></name><name><surname>Ali</surname><given-names>BR</given-names></name><name><surname>Bataineh</surname><given-names>MF</given-names></name></person-group><article-title>Extracellular molecular signals shaping dendrite architecture during brain development</article-title><source>Front Cell Dev Biol</source><year>2023</year><volume>11</volume><fpage>1254589</fpage><pub-id pub-id-type="doi">10.3389/fcell.2023.1254589</pub-id><pub-id pub-id-type="pmid">38155836</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Hamad MIK, Emerald BS, Kumar KK, Ibrahim MF, Ali BR, Bataineh MF. Extracellular molecular signals shaping dendrite architecture during brain development. Front Cell Dev Biol. 2023;11:1254589.<pub-id pub-id-type="pmid">38155836</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Agostinone</surname><given-names>J</given-names></name><name><surname>Alarcon-Martinez</surname><given-names>L</given-names></name><name><surname>Gamlin</surname><given-names>C</given-names></name><name><surname>Yu</surname><given-names>WQ</given-names></name><name><surname>Wong</surname><given-names>ROL</given-names></name><name><surname>Di Polo</surname><given-names>A</given-names></name></person-group><article-title>Insulin signalling promotes dendrite and synapse regeneration and restores circuit function after axonal injury</article-title><source>Brain</source><year>2018</year><volume>141</volume><fpage>1963</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1093/brain/awy142</pub-id><pub-id pub-id-type="pmid">29931057</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">Agostinone J, Alarcon-Martinez L, Gamlin C, Yu WQ, Wong ROL, Di Polo A. Insulin signalling promotes dendrite and synapse regeneration and restores circuit function after axonal injury. Brain. 2018;141:1963&#x02013;80.<pub-id pub-id-type="pmid">29931057</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Niblock</surname><given-names>MM</given-names></name><name><surname>Brunso-Bechtold</surname><given-names>JK</given-names></name><name><surname>Riddle</surname><given-names>DR</given-names></name></person-group><article-title>Insulin-like growth factor I stimulates dendritic growth in primary somatosensory cortex</article-title><source>J Neurosci</source><year>2000</year><volume>20</volume><fpage>4165</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.20-11-04165.2000</pub-id><pub-id pub-id-type="pmid">10818152</pub-id>
</element-citation><mixed-citation id="mc-CR63" publication-type="journal">Niblock MM, Brunso-Bechtold JK, Riddle DR. Insulin-like growth factor I stimulates dendritic growth in primary somatosensory cortex. J Neurosci. 2000;20:4165&#x02013;76.<pub-id pub-id-type="pmid">10818152</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Chiu</surname><given-names>SL</given-names></name><name><surname>Chen</surname><given-names>CM</given-names></name><name><surname>Cline</surname><given-names>HT</given-names></name></person-group><article-title>Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo</article-title><source>Neuron</source><year>2008</year><volume>58</volume><fpage>708</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2008.04.014</pub-id><pub-id pub-id-type="pmid">18549783</pub-id>
</element-citation><mixed-citation id="mc-CR64" publication-type="journal">Chiu SL, Chen CM, Cline HT. Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo. Neuron. 2008;58:708&#x02013;19.<pub-id pub-id-type="pmid">18549783</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Belforte</surname><given-names>N</given-names></name><name><surname>Agostinone</surname><given-names>J</given-names></name><name><surname>Alarcon-Martinez</surname><given-names>L</given-names></name><name><surname>Villafranca-Baughman</surname><given-names>D</given-names></name><name><surname>Dotigny</surname><given-names>F</given-names></name><name><surname>Cueva Vargas</surname><given-names>JL</given-names></name><etal/></person-group><article-title>AMPK hyperactivation promotes dendrite retraction, synaptic loss, and neuronal dysfunction in glaucoma</article-title><source>Mol Neurodegener</source><year>2021</year><volume>16</volume><fpage>43</fpage><pub-id pub-id-type="doi">10.1186/s13024-021-00466-z</pub-id><pub-id pub-id-type="pmid">34187514</pub-id>
</element-citation><mixed-citation id="mc-CR65" publication-type="journal">Belforte N, Agostinone J, Alarcon-Martinez L, Villafranca-Baughman D, Dotigny F, Cueva Vargas JL, et al. AMPK hyperactivation promotes dendrite retraction, synaptic loss, and neuronal dysfunction in glaucoma. Mol Neurodegener. 2021;16:43.<pub-id pub-id-type="pmid">34187514</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Ramamurthy</surname><given-names>S</given-names></name><name><surname>Chang</surname><given-names>E</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Ronnett</surname><given-names>GV</given-names></name></person-group><article-title>AMPK activation regulates neuronal structure in developing hippocampal neurons</article-title><source>Neuroscience</source><year>2014</year><volume>259</volume><fpage>13</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2013.11.048</pub-id><pub-id pub-id-type="pmid">24295634</pub-id>
</element-citation><mixed-citation id="mc-CR66" publication-type="journal">Ramamurthy S, Chang E, Cao Y, Zhu J, Ronnett GV. AMPK activation regulates neuronal structure in developing hippocampal neurons. Neuroscience. 2014;259:13&#x02013;24.<pub-id pub-id-type="pmid">24295634</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Gioran</surname><given-names>A</given-names></name><name><surname>Nicotera</surname><given-names>P</given-names></name><name><surname>Bano</surname><given-names>D</given-names></name></person-group><article-title>Impaired mitochondrial respiration promotes dendritic branching via the AMPK signaling pathway</article-title><source>Cell Death Dis</source><year>2014</year><volume>5</volume><fpage>e1175</fpage><pub-id pub-id-type="doi">10.1038/cddis.2014.144</pub-id><pub-id pub-id-type="pmid">24722300</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Gioran A, Nicotera P, Bano D. Impaired mitochondrial respiration promotes dendritic branching via the AMPK signaling pathway. Cell Death Dis. 2014;5:e1175.<pub-id pub-id-type="pmid">24722300</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Fukuda</surname><given-names>T</given-names></name><name><surname>Kosaka</surname><given-names>T</given-names></name></person-group><article-title>Gap junctions linking the dendritic network of GABAergic interneurons in the hippocampus</article-title><source>J Neurosci</source><year>2000</year><volume>20</volume><fpage>1519</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.20-04-01519.2000</pub-id><pub-id pub-id-type="pmid">10662841</pub-id>
</element-citation><mixed-citation id="mc-CR68" publication-type="journal">Fukuda T, Kosaka T. Gap junctions linking the dendritic network of GABAergic interneurons in the hippocampus. J Neurosci. 2000;20:1519&#x02013;28.<pub-id pub-id-type="pmid">10662841</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name><surname>Vervaeke</surname><given-names>K</given-names></name><name><surname>Lorincz</surname><given-names>A</given-names></name><name><surname>Nusser</surname><given-names>Z</given-names></name><name><surname>Silver</surname><given-names>RA</given-names></name></person-group><article-title>Gap junctions compensate for sublinear dendritic integration in an inhibitory network</article-title><source>Science</source><year>2012</year><volume>335</volume><fpage>1624</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1126/science.1215101</pub-id><pub-id pub-id-type="pmid">22403180</pub-id>
</element-citation><mixed-citation id="mc-CR69" publication-type="journal">Vervaeke K, Lorincz A, Nusser Z, Silver RA. Gap junctions compensate for sublinear dendritic integration in an inhibitory network. Science. 2012;335:1624&#x02013;8.<pub-id pub-id-type="pmid">22403180</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>MS</given-names></name><name><surname>Axelsen</surname><given-names>LN</given-names></name><name><surname>Sorgen</surname><given-names>PL</given-names></name><name><surname>Verma</surname><given-names>V</given-names></name><name><surname>Delmar</surname><given-names>M</given-names></name><name><surname>Holstein-Rathlou</surname><given-names>NH</given-names></name></person-group><article-title>Gap junctions</article-title><source>Compr Physiol</source><year>2012</year><volume>2</volume><fpage>1981</fpage><lpage>2035</lpage><pub-id pub-id-type="doi">10.1002/j.2040-4603.2012.tb00453.x</pub-id><pub-id pub-id-type="pmid">23723031</pub-id>
</element-citation><mixed-citation id="mc-CR70" publication-type="journal">Nielsen MS, Axelsen LN, Sorgen PL, Verma V, Delmar M, Holstein-Rathlou NH. Gap junctions. Compr Physiol. 2012;2:1981&#x02013;2035.<pub-id pub-id-type="pmid">23723031</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name><surname>Mei</surname><given-names>L</given-names></name><name><surname>Nave</surname><given-names>KA</given-names></name></person-group><article-title>Neuregulin-ERBB signaling in the nervous system and neuropsychiatric diseases</article-title><source>Neuron</source><year>2014</year><volume>83</volume><fpage>27</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2014.06.007</pub-id><pub-id pub-id-type="pmid">24991953</pub-id>
</element-citation><mixed-citation id="mc-CR71" publication-type="journal">Mei L, Nave KA. Neuregulin-ERBB signaling in the nervous system and neuropsychiatric diseases. Neuron. 2014;83:27&#x02013;49.<pub-id pub-id-type="pmid">24991953</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name><surname>Yokoi</surname><given-names>S</given-names></name><name><surname>Udagawa</surname><given-names>T</given-names></name><name><surname>Fujioka</surname><given-names>Y</given-names></name><name><surname>Honda</surname><given-names>D</given-names></name><name><surname>Okado</surname><given-names>H</given-names></name><name><surname>Watanabe</surname><given-names>H</given-names></name><etal/></person-group><article-title>3&#x02019;UTR Length-Dependent Control of SynGAP Isoform alpha2 mRNA by FUS and ELAV-like Proteins Promotes Dendritic Spine Maturation and Cognitive Function</article-title><source>Cell Rep</source><year>2017</year><volume>20</volume><fpage>3071</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.08.100</pub-id><pub-id pub-id-type="pmid">28954225</pub-id>
</element-citation><mixed-citation id="mc-CR72" publication-type="journal">Yokoi S, Udagawa T, Fujioka Y, Honda D, Okado H, Watanabe H, et al. 3&#x02019;UTR Length-Dependent Control of SynGAP Isoform alpha2 mRNA by FUS and ELAV-like Proteins Promotes Dendritic Spine Maturation and Cognitive Function. Cell Rep. 2017;20:3071&#x02013;84.<pub-id pub-id-type="pmid">28954225</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name><surname>Zybura-Broda</surname><given-names>K</given-names></name><name><surname>Wolder-Gontarek</surname><given-names>M</given-names></name><name><surname>Ambrozek-Latecka</surname><given-names>M</given-names></name><name><surname>Choros</surname><given-names>A</given-names></name><name><surname>Bogusz</surname><given-names>A</given-names></name><name><surname>Wilemska-Dziaduszycka</surname><given-names>J</given-names></name><etal/></person-group><article-title>HuR (Elavl1) and HuB (Elavl2) Stabilize Matrix Metalloproteinase-9 mRNA During Seizure-Induced Mmp-9 Expression in Neurons</article-title><source>Front Neurosci</source><year>2018</year><volume>12</volume><fpage>224</fpage><pub-id pub-id-type="doi">10.3389/fnins.2018.00224</pub-id><pub-id pub-id-type="pmid">29686606</pub-id>
</element-citation><mixed-citation id="mc-CR73" publication-type="journal">Zybura-Broda K, Wolder-Gontarek M, Ambrozek-Latecka M, Choros A, Bogusz A, Wilemska-Dziaduszycka J, et al. HuR (Elavl1) and HuB (Elavl2) Stabilize Matrix Metalloproteinase-9 mRNA During Seizure-Induced Mmp-9 Expression in Neurons. Front Neurosci. 2018;12:224.<pub-id pub-id-type="pmid">29686606</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name><surname>Mulligan</surname><given-names>MR</given-names></name><name><surname>Bicknell</surname><given-names>LS</given-names></name></person-group><article-title>The molecular genetics of nELAVL in brain development and disease</article-title><source>Eur J Hum Genet</source><year>2023</year><volume>31</volume><fpage>1209</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1038/s41431-023-01456-z</pub-id><pub-id pub-id-type="pmid">37697079</pub-id>
</element-citation><mixed-citation id="mc-CR74" publication-type="journal">Mulligan MR, Bicknell LS. The molecular genetics of nELAVL in brain development and disease. Eur J Hum Genet. 2023;31:1209&#x02013;17.<pub-id pub-id-type="pmid">37697079</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name><surname>Berto</surname><given-names>S</given-names></name><name><surname>Usui</surname><given-names>N</given-names></name><name><surname>Konopka</surname><given-names>G</given-names></name><name><surname>Fogel</surname><given-names>BL</given-names></name></person-group><article-title>ELAVL2-regulated transcriptional and splicing networks in human neurons link neurodevelopment and autism</article-title><source>Hum Mol Genet</source><year>2016</year><volume>25</volume><fpage>2451</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">27260404</pub-id>
</element-citation><mixed-citation id="mc-CR75" publication-type="journal">Berto S, Usui N, Konopka G, Fogel BL. ELAVL2-regulated transcriptional and splicing networks in human neurons link neurodevelopment and autism. Hum Mol Genet. 2016;25:2451&#x02013;64.<pub-id pub-id-type="pmid">27260404</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>Z</given-names></name><name><surname>Srivastava</surname><given-names>DP</given-names></name><name><surname>Photowala</surname><given-names>H</given-names></name><name><surname>Kai</surname><given-names>L</given-names></name><name><surname>Cahill</surname><given-names>ME</given-names></name><name><surname>Woolfrey</surname><given-names>KM</given-names></name><etal/></person-group><article-title>Kalirin-7 controls activity-dependent structural and functional plasticity of dendritic spines</article-title><source>Neuron</source><year>2007</year><volume>56</volume><fpage>640</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2007.10.005</pub-id><pub-id pub-id-type="pmid">18031682</pub-id>
</element-citation><mixed-citation id="mc-CR76" publication-type="journal">Xie Z, Srivastava DP, Photowala H, Kai L, Cahill ME, Woolfrey KM, et al. Kalirin-7 controls activity-dependent structural and functional plasticity of dendritic spines. Neuron. 2007;56:640&#x02013;56.<pub-id pub-id-type="pmid">18031682</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name><surname>Herring</surname><given-names>BE</given-names></name><name><surname>Nicoll</surname><given-names>RA</given-names></name></person-group><article-title>Kalirin and Trio proteins serve critical roles in excitatory synaptic transmission and LTP</article-title><source>Proc Natl Acad Sci USA</source><year>2016</year><volume>113</volume><fpage>2264</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1073/pnas.1600179113</pub-id><pub-id pub-id-type="pmid">26858404</pub-id>
</element-citation><mixed-citation id="mc-CR77" publication-type="journal">Herring BE, Nicoll RA. Kalirin and Trio proteins serve critical roles in excitatory synaptic transmission and LTP. Proc Natl Acad Sci USA. 2016;113:2264&#x02013;9.<pub-id pub-id-type="pmid">26858404</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name><surname>Budnik</surname><given-names>V</given-names></name><name><surname>Salinas</surname><given-names>PC</given-names></name></person-group><article-title>Wnt signaling during synaptic development and plasticity</article-title><source>Curr Opin Neurobiol</source><year>2011</year><volume>21</volume><fpage>151</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.conb.2010.12.002</pub-id><pub-id pub-id-type="pmid">21239163</pub-id>
</element-citation><mixed-citation id="mc-CR78" publication-type="journal">Budnik V, Salinas PC. Wnt signaling during synaptic development and plasticity. Curr Opin Neurobiol. 2011;21:151&#x02013;9.<pub-id pub-id-type="pmid">21239163</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name><surname>Ochs</surname><given-names>SM</given-names></name><name><surname>Dorostkar</surname><given-names>MM</given-names></name><name><surname>Aramuni</surname><given-names>G</given-names></name><name><surname>Schon</surname><given-names>C</given-names></name><name><surname>Filser</surname><given-names>S</given-names></name><name><surname>Poschl</surname><given-names>J</given-names></name><etal/></person-group><article-title>Loss of neuronal GSK3beta reduces dendritic spine stability and attenuates excitatory synaptic transmission via beta-catenin</article-title><source>Mol Psychiatry</source><year>2015</year><volume>20</volume><fpage>482</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/mp.2014.55</pub-id><pub-id pub-id-type="pmid">24912492</pub-id>
</element-citation><mixed-citation id="mc-CR79" publication-type="journal">Ochs SM, Dorostkar MM, Aramuni G, Schon C, Filser S, Poschl J, et al. Loss of neuronal GSK3beta reduces dendritic spine stability and attenuates excitatory synaptic transmission via beta-catenin. Mol Psychiatry. 2015;20:482&#x02013;9.<pub-id pub-id-type="pmid">24912492</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name><surname>Salinas</surname><given-names>PC</given-names></name><name><surname>Hall</surname><given-names>AC</given-names></name></person-group><article-title>Lithium and synaptic plasticity</article-title><source>Bipolar Disord</source><year>1999</year><volume>1</volume><fpage>87</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1034/j.1399-5618.1999.010205.x</pub-id><pub-id pub-id-type="pmid">11252664</pub-id>
</element-citation><mixed-citation id="mc-CR80" publication-type="journal">Salinas PC, Hall AC. Lithium and synaptic plasticity. Bipolar Disord. 1999;1:87&#x02013;90.<pub-id pub-id-type="pmid">11252664</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name><surname>Alda</surname><given-names>M</given-names></name></person-group><article-title>Lithium in the treatment of bipolar disorder: pharmacology and pharmacogenetics</article-title><source>Mol Psychiatry</source><year>2015</year><volume>20</volume><fpage>661</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1038/mp.2015.4</pub-id><pub-id pub-id-type="pmid">25687772</pub-id>
</element-citation><mixed-citation id="mc-CR81" publication-type="journal">Alda M. Lithium in the treatment of bipolar disorder: pharmacology and pharmacogenetics. Mol Psychiatry. 2015;20:661&#x02013;70.<pub-id pub-id-type="pmid">25687772</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name><surname>Lenox</surname><given-names>RH</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name></person-group><article-title>Molecular basis of lithium action: integration of lithium-responsive signaling and gene expression networks</article-title><source>Mol Psychiatry</source><year>2003</year><volume>8</volume><fpage>135</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1038/sj.mp.4001306</pub-id><pub-id pub-id-type="pmid">12610644</pub-id>
</element-citation><mixed-citation id="mc-CR82" publication-type="journal">Lenox RH, Wang L. Molecular basis of lithium action: integration of lithium-responsive signaling and gene expression networks. Mol Psychiatry. 2003;8:135&#x02013;44.<pub-id pub-id-type="pmid">12610644</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><mixed-citation publication-type="other">Won E, Kim YK An Oldie but Goodie: Lithium in the Treatment of Bipolar Disorder through Neuroprotective and Neurotrophic Mechanisms. Int J Mol Sci. 2017;18:2679.</mixed-citation></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name><surname>Malhi</surname><given-names>GS</given-names></name><name><surname>Tanious</surname><given-names>M</given-names></name><name><surname>Das</surname><given-names>P</given-names></name><name><surname>Coulston</surname><given-names>CM</given-names></name><name><surname>Berk</surname><given-names>M</given-names></name></person-group><article-title>Potential mechanisms of action of lithium in bipolar disorder. Current understanding</article-title><source>CNS Drugs</source><year>2013</year><volume>27</volume><fpage>135</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1007/s40263-013-0039-0</pub-id><pub-id pub-id-type="pmid">23371914</pub-id>
</element-citation><mixed-citation id="mc-CR84" publication-type="journal">Malhi GS, Tanious M, Das P, Coulston CM, Berk M. Potential mechanisms of action of lithium in bipolar disorder. Current understanding. CNS Drugs. 2013;27:135&#x02013;53.<pub-id pub-id-type="pmid">23371914</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name><surname>Woods</surname><given-names>YL</given-names></name><name><surname>Cohen</surname><given-names>P</given-names></name><name><surname>Becker</surname><given-names>W</given-names></name><name><surname>Jakes</surname><given-names>R</given-names></name><name><surname>Goedert</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase</article-title><source>Biochem J</source><year>2001</year><volume>355</volume><fpage>609</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1042/bj3550609</pub-id><pub-id pub-id-type="pmid">11311121</pub-id>
</element-citation><mixed-citation id="mc-CR85" publication-type="journal">Woods YL, Cohen P, Becker W, Jakes R, Goedert M, Wang X, et al. The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase. Biochem J. 2001;355:609&#x02013;15.<pub-id pub-id-type="pmid">11311121</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><mixed-citation publication-type="other">Ioannidis V, Pandey R, Bauer HF, Schon M, Bockmann J, Boeckers TM <italic>et al</italic>. Disrupted extracellular matrix and cell cycle genes in autism-associated Shank3 deficiency are targeted by lithium. Mol Psychiatry. 2024;29:704&#x02013;17.</mixed-citation></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Smith</surname><given-names>CB</given-names></name></person-group><article-title>Lithium: a promising treatment for fragile X syndrome</article-title><source>ACS Chem Neurosci</source><year>2014</year><volume>5</volume><fpage>477</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1021/cn500077p</pub-id><pub-id pub-id-type="pmid">24814569</pub-id>
</element-citation><mixed-citation id="mc-CR87" publication-type="journal">Liu Z, Smith CB. Lithium: a promising treatment for fragile X syndrome. ACS Chem Neurosci. 2014;5:477&#x02013;83.<pub-id pub-id-type="pmid">24814569</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>